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Abstract 
The initial step of HIV entry into host cells involves the specific binding of gp120 
envelope glycoprotein to the cell-surface CD4 protein, expressed by antigen-
presenting cells. Extensive systemic infection of host cells by HIV leads to immune 
dysfunction and ultimately the demise of infected individuals due to AIDS.  
The gp120-CD4 interaction (KD of approximately 2 X 10
-9 M) is of primary importance 
to the infection process of HIV and poses a validated therapeutic target. Mutational 
analyses of CD4 show that residues in domains 1 and 2 of CD4 contribute to gp120 
binding. Soluble CD4 protein, composed of domains 1 and 2 or 1 to 4 only, has been 
shown to compete with cell-surface CD4 for gp120 binding and inhibit host cell 
infection. Soluble CD4 achieves viral inhibition by uncoating HIV of its envelope 
proteins, reducing the amount of cell-surface CD4 recognition by gp120 and 
preventing the cell-to-cell spread of HIV by syncytium formation. Due to the short 
serum-lifetime of soluble CD4 in the blood, modified forms of it have been generated 
which contain life-time extending immunoglobulin portions attached to them. The 
attachment of soluble CD4 in place of immunoglobulin variable regions may increase 
the valence of CD4 available for gp120 binding and may contribute extra immune 
effector functions depending on the Fc portion type.   
PRO 542 (CD4-IgG2), composed of four two-domain CD4 molecules replacing the 
variable regions of antibody IgG2, was found to have greater valence and effector 
functions than soluble CD4. Like soluble CD4, PRO 542 was deemed safe at all 
concentrations tested during clinical trials; however tests were halted as it could not 
significantly reduce viral load in patients. In this study, we designed constructs which 
produced a PRO 542-like protein (kCD4-IgG2wt) in a novel way. Constructs encoding 
a mutant S60C PRO 542-like molecule (kCD4-IgG2S60C) were also generated to 
produce a heterotetramer intended to bind gp120 with even higher affinity by virtue 
of intermolecular redox-disulphide exchange. The uniquely produced 
heterotetrameric kCD4-IgG2wt and kCD4-IgG2S60C proteins were expressed in 
Human Embryonic Kidney 293T cells and collected in culture supernatant. 
Purification of kCD4-IgG2wt and kCD4-IgG2S60C was of limited success; however 
both proteins could bind Protein-A agarose beads like NIH PRO 542 implying that 
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their Fc portions were fully folded. Immunoprecipitation tests showed the ability of 
kCD4-IgG2wt to bind gp120 from HIV-1Bal like PRO 542 confirming the high structural 
and functional integrity of kCD4-IgG2wt. Finally, surface plasmon resonance studies 
(SPR) were conducted to evaluate the ability of supernatant-contained kCD4-IgG2wt 
and kCD4-IgG2S60C to bind six different gp120 molecules from genetically diverse 
viruses.  SPR studies included purified PRO 542 obtained from the National 
Institutes of Health (NIH), two-domain CD4 (2dCD4wt) and an S60C mutant two-
domain CD4 (2dCD4S60C) as positive controls. The culture supernatant from mock 
transfections was used as a negative control. According to SPR data, supernatant-
containing kCD4-IgG2wt binds specifically to gp120 of HIV-1CN54, HIV-1SF162, HIV-
1IN25925, HIV-1ZA706010164, HIV-196ZM651 and HIV-1Bal like NIH PRO 542, 2dsCD4
wt and 
2dsCD4S60C. Monoclonal antibody 17b, which binds the co-receptor binding site of 
gp120 was observed to bind gp120 from HIV-1SF162, HIV-1IN25925, HIV-1ZA706010164 and 
HIV-1Bal, after the gp120s co-receptor binding site was exposed by supernatant-
contained kCD4-IgG2wt, NIH PRO 542, 2dsCD4wt and 2dsCD4S60C. Low 
concentrations of expressed kCD4-IgGS60C did not permit the observation of kCD4-
IgG2S60C binding to any of the tested gp120s. 
Results obtained from this study showed that the novel strategies employed to 
produce heterotetrameric kCD4-IgG2wt, which was identical in structure and function 
to NIH PRO 542, were successful. Novel and functional CD4-based molecules with 
activity against HIV gp120 may be generated using the strategies described in this 
study. 
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1.1 History of HIV and AIDS 
Acquired immunodeficiency syndrome (AIDS), first described in 1981, is a unique 
disease state which arises when CD4+ T-lymphocytes are severely depleted in 
persons infected with the human immunodeficiency virus (HIV). Over time, the 
reduction in CD4+ T-lymphocytes leaves the infected individual highly susceptible to 
a variety of opportunistic infections and or malignancies which, if left untreated, 
eventually leads to their death [1, 2]. Within a few years after the first reports in 1981, 
HIV infection was described in most countries in the world, and was classified as a 
pandemic. The latest data shows that by the end of 2009, 32.8 million people world-
wide were estimated to be living with HIV and approximately 68% of them were from 
Sub-Saharan Africa (www.unaids.org) [3, 4].  
 
 
1.2 Structural organisation of HIV 
The overall shape of HIV is spherical, with a diameter of between 100 and 120 nm 
[5, 6]. HIV belongs to the family Retroviridae, as it has a genome consisting of two 
single-stranded plus RNA molecules, which are reverse transcribed to DNA 
molecules by the viral enzyme reverse transcriptase (Figure 1.1). The RNA genome 
is encapsulated in a capsid (p24). Surrounding the p24 is the p17 (an outer matrix 
protein), which is further encased within the viral membrane comprised of the viral 
gp120 and gp41 envelope glycoproteins and host derived membrane [7-10].  
 
To fulfil other requirements for successful infection of host cells, HIV carries three 
enzymes within the capsid; protease, integrase and reverse transcriptase derived 
from the pol gene (Figure 1.1). The protease enzyme is essential for the cleavage of 
Gag-Pol polyproteins during the assembly and maturation of virions while reverse 
transcriptase and integrase are necessary for viral DNA synthesis and integration, 
respectively. The regulatory Tat and Rev proteins are critical for regulating the 
infection processes, along with Nef, Vif and Vpu as accessory proteins that function 
as virulence factors [8, 10, 11]. 
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Figure 1.1: Structural organisation of an HIV virion, image obtained from 
Papathanasopoulos (2009) [10]. 
 
1.3 HIV life-cycle 
Generally, individuals acquire HIV through sexual (heterosexual and homosexual) 
contact with an HIV infected person. Other modes of transmission include mother to 
child transmission, and contact with infected blood. In sexual transmission, HIV is 
passed through the genito-urinary mucosal surfaces of the infected person to an 
uninfected person, allowing virus particles access and attachment to CD4+ T-
lymphocytes, dendritic cells or macrophages [12]. To initiate entry, the viral surface 
envelope glycoprotein gp120 sequentially binds CD4 and a co-receptor, either CCR5 
or CXCR4, on the surface of the host cell. Following attachment to the host 
receptors, the formation of the six helix bundle in the transmembrane glycoprotein 
gp41 and subsequent fusion of the viral and host membranes occurs [13-17].  
 
The viral p24 capsid core is then introduced into the host cell cytoplasm where it 
uncoats to release the error-prone reverse transcriptase (among other proteins) for 
commencement of viral cDNA generation [18]. After the viral cDNA is synthesized; 
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integrase, Vpr and a range of host proteins assemble to form the pre-integration 
complex. The pre-integration complex moves into the nucleus where the viral cDNA 
is irreversibly integrated into the host cell genome by the integrase enzyme. When 
the cell with integrated viral cDNA becomes transcriptionally active, all viral mRNAs 
are efficiently exported to the cytoplasm where viral proteins are synthesized. The 
Gag-pol polyprotein is cleaved by the viral protease as required, whereas the viral 
envelope glycoprotein (env) is produced as a hyperglycosylated gp160 precursor 
that undergoes proteolytic cleavage in the Golgi apparatus by host proteases to 
generate gp120 and gp41 subunits, which then assemble into non-covalently 
attached heterotrimers [14, 19, 20].  
 
Immature virions are ultimately assembled and bud out taking a portion of the host 
membrane with them, within which the gp120 and gp41 subunits are embedded [17, 
21, 22].   Subsequently, the viral protease completes the Gag cleavage sequence to 
form mature virions capable of new rounds of infection.  If the host cell is not 
transcriptionally active, the viral DNA remains embedded in the host genome and 
acts as a reservoir for latent infections. One replication cycle takes approximately 2.5 
days, and one infected cell can produce up to 130 000 new virions [23-28]. 
 
1.4 Genetic variation of HIV 
The inability of the reverse transcriptase enzyme to proof-read the cDNA sequences 
it generates, results in the generation of diverse forms of the virus during each 
replication cycle. Coupled with the high replicative capacity and immune selective 
pressures of the host, one finds the diversity of HIV increasing over time. There are 
two types of HIV:  HIV type 1 (HIV-1) and HIV type 2 (HIV-2). Within HIV-1, there are 
four major groups of HIV-1 , namely M (major), N (non-major), O (outlier) and P, 
while HIV-2 is subdivided into groups A to G (http://www.hiv.lanl.gov) [3, 4]. Infection 
with HIV-1 group M is responsible for the major pandemic worldwide [29].  
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Within group M alone there are 9 subtypes: A to D, F to H, J and K. The gag genes 
of all the subtypes within HIV-1 group M have approximately 15% differences in 
sequence and approximately 25% differences in their env gene sequences on 
average between each other [30-36]. Some subtypes are closer in sequence identity 
than others and even within subtypes; sub-groups can be distinguished, namely sub-
subtypes A1 and A2 and sub-subtypes F1 and F2. Notably, subtypes are 
geographically dispersed. For instance; subtype A of HIV-1 has been isolated around 
Central Africa, subtype B in North America and Europe, whereas subtype C 
predominates in Southern Africa and India. Some subtypes are generally found 
within single countries such as subtypes F, G, J and K; which are found in Romania, 
Russia, Democratic Republic of Congo and Cameroon, respectively [3, 37]. A small 
number of subtypes have been identified within group O, but an even lesser amount 
has been found within group N [38].  
 
Because retroviruses have high propensity to recombine, numerous viruses 
composed of genetic structures from two or more separate subtypes have often 
been identified. If these are found in only one dually-infected (or multiply-infected) 
individual, they are called a unique recombinant form (URF). If an inter-subtype 
recombinant is transmitted to many individuals, and eventually infects three or more 
persons who are not epidemiologically related, they become one of the circulating 
recombinant forms (CRF). To date, 51 CRFs have been characterised within group 
M isolates of HIV-1 alone, and one CRF within HIV-2 
(http://www.hiv.lanl.gov/content/sequence) [3, 4, 37, 39-42]. 
 
1.5 Clinical progression of individuals infected with HIV-1 
Throughout the course of HIV infection, a number of different stages of disease 
progress are observed (Figure 1.2) [43]. 
After transmission of HIV, the stage of acute HIV infection commences and may last 
a minimum of two weeks and a maximum of approximately 6 months. HIV infected 
persons experience similar symptoms to person infected with the Influenza virus 
[44]. In this phase, the virus replicates vigorously and depletes the number of CD4+ 
21 
 
T-lymphocytes in the gut-associated lymphoid tissue (GALT), the primary HIV 
replication site [12]. The expansion of the viral population is curtailed somewhat by 
the action of cytotoxic T-lymphocytes (CTLs) and HIV-specific antibodies which are 
recruited by the body to fight the infection [43, 45-47].  
The period that follows after acute infection is the clinically asymptomatic stage. In 
this stage, infected person may recover a large number of their CD4+ T-lymphocytes 
and establish a viral load set-point [10]. The level of the viral load set-point has been 
regarded as an important determinant in the progression of infected persons to 
AIDS. Infected person with lower viral load set-points tend to survive longer than 
those with higher set-points. Infected individuals may remain in this stage of infection 
for up to 10 years while remaining infectious (Clinical latency) (Figure 1.2). Towards 
the end of the asymptomatic stage, large numbers of CD4+ T cells are once again 
reached [10, 47, 48].  
Once the levels of CD4+ T cells are severely reduced, the infected person 
experiences symptoms from opportunistic infections or malignancies such as 
Tuberculosis, Candidiasis and Kaposi sarcoma. This stage of immune vulnerability is 
referred to as the symptomatic stage, with persons generally having a CD4 count of 
less than 200 CD4+ T cells per cubic millilitre of blood (a normal CD4 count is 1000)  
and indicates the onset of AIDS [10, 49]. The host immune system then boosts the 
fight against HIV infection using humoral or cellular responses; however these 
interventions arise too late in the infection process and rarely suppress the infection 
completely [43]. In this late stage of infection, virions arise which may employ an 
alternative chemokine co-receptor, CXCR4, or both CXCR4 and CCR5, further 
establishing the AIDS state [22, 50]. If the infected persons are not provided with 
highly active-antiretroviral therapy (HAART) before the symptomatic stage is reach, 
they generally have increased morbidity and mortality. It is observed that the earlier 
infected persons are placed on HAART, the slower the progression to AIDS will be. 
Person entering the AIDS stage of infection rarely survive more than two years 
without treatment [10, 51-53].  
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Figure 1.2: The disease progression profile of HIV infected individuals 
obtained from Fauci (1993) [43]. 
 
1.6 Treatment options against HIV-1 infection 
To date, there is no cure for HIV-1 infection, however over twenty-five different 
agents have obtained FDA approval for clinical use in the fight against HIV. The 
twenty-five compounds could be divided into six different categories according to the 
targets they act upon [54].  
 
1.6.1 Reverse transcriptase inhibitors 
The nucleoside reverse transcriptase inhibitors (Zidovudine, Didanosine, Zalcitabine, 
Stavudine, Lamivudine, Abacivir and Emtricitabine), non-nucleoside reverse 
transcriptase inhibitors (Nevirapine, Delavirdine, Efavirenz and Etravirine), and the 
nucleotide reverse transcriptase inhibitor Tenofovir target and suppress the 
functioning of HIV reverse transcriptase enzyme [54-57].  
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1.6.2 Protease inhibitors 
To counteract the functioning of the protease enzyme, the inhibitors; Saquinavir, 
Ritonavir, Indinavir, Nelfinavir, Amprenavir, Lopinavir, Atazanavir, Fosamprenavir, 
Tipranavir and Darunavir are available [54-56].  
 
1.6.3 Integrase inhibitors 
There is only one clinically available drug targeting the HIV integrase enzyme, which 
is Raltegravir [54-58].  
 
1.6.4 Entry inhibitors 
Two entry inhibitors currently have FDA approval: Enfuvirtide, a fusion inhibitor, and 
Maraviroc, a CCR5 antagonist (www.fda.gov/oashi/aids/virals.html) [59-64].  
The G-protein coupled transmembrane CCR5 receptor acts a high affinity receptor 
for the RANTES and MIP1α, but also assists HIV in entering host cells by acting as a 
secondary receptor for gp120. The non-peptidic Maraviroc molecule is the first FDA 
approved CCR5 antagonist, having the ability to prevent HIV gp120 from using the 
co-receptor binding site (CoRbs) of CCR5 for viral entry processes in a non-
competitive manner [65]. Only treatment experienced individuals, harbouring R5 
viruses are eligible for salvage treatment with Maraviroc [54, 59, 65-72]. Patients 
with combinations of R5 and X4 viruses are barred from using Maraviroc as it is 
feared that they will develop selective pressures in favour of X4 viruses, which are 
not antagonised by Maraviroc. It is unclear if Maraviroc has the potential to induce a 
change in co-receptor preferences of HIV itself [54, 59, 61, 65, 72-78]. It has not 
been investigated if long-term usage of Maraviroc may have oncologic and 
immunologic disadvantages, however this HIV inhibitor has encouraged the 
development of other CCR5 antagonists such as Vicriviroc (currently in phase 3 
clinical trials) [54-57, 67, 69].  
 
The gp41 subunit of env responsible for HIV fusing to host cells is approximately 345 
amino acids in length and is organised into three major substructures. The fusion 
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protein is composed of an ectodomain, a transmembrane domain and a C-terminal 
domain. The ectodomain contains a hydrophobic fusion peptide, a polar region, two 
heptad repeat regions (HR1 and HR2) and a membrane proximal exterior region 
(MPER) [79]. The HR1 and HR2 regions which are connected together by a 
disulphide bond within a hydrophilic region between them. The conformational 
changes induced by gp120 binding to CD4 ultimately lead to the bundling together of 
three HR1 regions. Thereafter, a hydrophobic groove between the HR1 and HR2 
regions folds upon itself which allows the two regions to associate in an anti-parallel 
fashion, promoting the formation of a six-helical bundle. The formation of the six-
helical bundle drives the fusion of host cell and viral membranes [79-81].  
 
Enfuvirtide (T-20) is another drug approved by the FDA which prevents HIV entry 
into host cells [54, 58]. T-20 is generated by synthesizing a peptide which has the 
same sequence as the HR2 region of gp120. When the six-helical bundle starts to 
form during the fusion process, T-20 disrupts the association of the bundles by 
binding to the HR1 regions [63, 82]. There were no cytotoxic effects observed in in 
vitro tests of T-20 against HIV. In association with an optimized antiretroviral regime, 
T-20 provides treatment experienced patients with greater than 1. 6 log10 reductions 
in viral load compared to control groups who only had a 0.764 log10 reduction [63, 
64, 82-92]. Resistance to T-20 is known to occur, however the viruses that are 
resistant to T-20 are generally less fit [63]. In order to reduce the potential of T-20 
strains arising, one needs to design peptides which bind more stably to gp41 HR1 
and suppress replication of virus greatly. Oligomers or peptides that target the six-
helical bundle have been shown to have greater viral suppression activity against 
HIV. The oligomers have improved helical stabilization motifs making binding to the 
HR1 regions stronger, in some cases 3600 fold better than the activity of T-20 on the 
same target. In future, oligomeric gp41 antagonists may improve our armamentarium 
of entry inhibitors [93]. 
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1.6.5 Highly active antiretroviral treatment (HAART) 
Drug regimens comprised of a minimum of three antiretroviral drugs from the 
different aforementioned categories, given to AIDS patients to extend their lifetime is 
known as HAART [54-58]. For example, first line regimens will incorporate two 
nucleoside reverse transcriptase inhibitors, and one non-nucleoside reverse 
transcriptase inhibitor. Notwithstanding the large amount of therapies available to 
treat and extend the lives of HIV positive patients, drug resistance and treatment 
failures still arise. Unfortunately, HAART requires the patient to adhere stringently to 
the therapy for the rest of their lives, may provide harmful side-effects and the 
potential to allow drug-resistant variants to arise [72, 87]. Other treatments are being 
developed to provide more sterilizing and functional cures of HIV [10, 54, 56, 57, 94]. 
 
1.7 Novel strategies to prevent viral entry 
An improved understanding of the interaction between the viral envelope 
glycoprotein and the host cell has implications for vaccine immunogen design as well 
as novel antiretroviral drug design. The attachment process of HIV to host cells is 
largely dependent on gp120 interacting with CD4 to reveal the gp120 co-receptor 
binding site (CoRbs), so that it may interact with a chemokine receptor, either CCR5 
or CXCR4. All HIV-1 strains require CD4 to initiate entry (with the exception of 
viruses infecting neural tissue) [95-98], making the CD4-gp120 interaction an 
important antiretroviral drug target. 
 
1.7.1 Cell-surface CD4  
Cell-surface CD4 receptors naturally interact with major histocompatibility complex II 
(MHC II) in antigen recognition processes facilitated by thymus derived lymphocytes 
(T-lymphocytes). Monocytes and macrophages also have CD4 receptors on their 
surfaces, but are distributed in lesser amounts relative to T-lymphocytes [99].  
Distinct features of the non-polymorphic 55 kDa CD4 protein are the four tandem 
extracellular domains which comprise of 372 amino acids,  resembling the domains 
of immunoglobulins and twenty-three transmembrane amino acids that are 
connected to a thirty-eight amino acid cytoplasmic segment [100, 101]. HIV subverts 
the normal functioning of CD4 as an antigen-presenting agent and uses it as a 
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primary receptor for attachment to host cells [102]. The affinity and avidity of gp120 
for CD4 is high, providing the interaction with a relatively low dissociation constant of 
approximately 10-9 M [103, 104]. 
 
1.7.2 Structure of gp120-CD4 complexes 
The gp120 molecule is composed of five variable regions and five constant regions. 
There are nine or ten possible disulphide bonds in the gp120 molecule which assist 
in the folding and or functioning of the protein. The C1 region of gp120 has a 
disulphide bond between residues 54 and 57; region C2 has disulphide bonds 
between residues 218-247 and 228 and 239. One disulphide bond links the C3 and 
C4 regions while a disulphide bond is found at the base of V3 and V4 regions also 
[105]. Loops of the gp120 molecule comprise of 3 disulphide bonds between 
residues 119 and 205, residues 129 and 196 as well as residues 131 and 157 [105-
107]. Not all the disulphide bonds of gp120 are important for functioning. In fact, only 
five disulphides are important for the functioning of gp120 while the other four or five 
disulphides contribute to the structural integrity of the protein only. Two disulphide 
bonds of gp120 do not contribute to the replication or the functioning of the virus and 
those are between residues 119 and 205 as well as 378-445, however; the 
disulphide bonds of residues 57-74, 218-247, 228-239 and 296-331 are important for 
proper functioning and replication of viruses. Mutation of the disulphides between 
residues 126-196, 131-157 and 598-604 allow the protein to fold properly, however 
removal of any of these three disulphides do not provide the virus with the capability 
of replicating [105, 107].  
The crystal structure of core gp120, derived from an HIV-1 clade B HXBC2 strain, in 
complex with 2dsCD4 and antibody 17b was solved in 1998 by Kwong et al (Figure 
1.3) [106]. The structure elucidated how the conformational changes of gp120 
protein are induced post-CD4 engagement and how the co-receptor binding site may 
be exposed for interaction with a chemokine receptor [106, 108, 109]. The gp120 
protein that was crystallised with CD4 and antibody 17b was extensively modified, 
however, with variable regions and termini severely truncated, and glycosylation 
sites altered [22, 106]. 
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Created by the interface of the inner and outer domains of gp120 is a hydrophobic 
binding pocket that is specific for binding CD4 protein (Figure 1.3), which provides 
HIV with the capability of attaching to CD4+ T-lymphocytes, monocytes, dendritic 
cells and brain microglia [106]. Upon binding, phenylalanine 43 of CD4 enters deep 
inside the gp120 binding pocket, making extensive contacts with a number of gp120 
residues. The contacts made by CD4 within the CD4 binding site (CD4bs) equate to 
approximately 800 Å2 of the gp120 surface [106]. Following CD4 binding the V2 loop 
of gp120 moves from occluding the CD4 induced epitope (CD4i), the V3 loop and the 
bridging sheet mini-domain. The V2 and V3 loops move in such a way as to expose 
and stabilize the chemokine receptor binding site, after CD4 binding. Monoclonal 
antibody 17b was found to bind the CD4i more readily after CD4 had bound gp120 
(Figure 1.3), however minimal binding may still be accomplished without the 
conformational changes induced by CD4 binding to gp120 [22, 106, 110].  
 
 
Figure 1.3: Structure of HIV-1HXBC2 gp120 in complex with 2dsCD4 and antibody 
17b. The crystal structure of 2dsCD4 and the CD4i antibody 17b bound to gp120 
(PDB ID: 1G9M) was generated by Kwong et al (1998) [106]. The image was viewed 
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using The PyMOL Molecular Graphics System, evaluation version 1. 2. 8, 
Schrodinger, LCC. The gp120 protein is coloured red whilst 2dsCD4 and antibody 
17b are coloured blue and green respectively. 
 
Several other models, crystal structures and cryoEM tomography structures have 
been published of unliganded gp120 and gp120 in complex with antibodies, which 
have assisted with the elucidation of the conformation changes undertaken by gp120 
during host cell attachment [6, 14, 17, 21, 106, 108, 111-117]. The structures have 
further helped elucidate the conformations and epitopes within gp120 that are 
necessary for the entry process, as well as the mechanisms of antibody mediated 
neutralization.   
 
1.7.3 HIV-1 neutralising antibodies to prevent CD4 mediated viral entry  
In time, it may be possible to reduce HIV infection by virtue of a vaccine; however 
current attempts at eliciting vigorous antibody responses against HIV have been 
disappointing. HIV has the ability to mask multiple conserved epitopes with a glycan 
shield in its outer domain and evolve its sequences by mutations [14, 118]. It is, 
therefore, difficult for the adaptive immune response to combat the virus effectively. 
Pre-exposure prophylaxes seem to be attractive interventions to reduce HIV infection 
as they protect individuals from contracting the virus or prime their immune systems 
for the infection [119-126].  A comprehensive, tiered categorization of HIV-1 isolates 
has been created to organise viral strains and subtypes according to their 
sensitivities of neutralisations. Tier 1 isolates are most susceptible, tier 2 viruses 
moderately susceptible and tier 3 viruses are least susceptible to neutralisation by 
known antibodies. It is envisioned that vaccine design will be based on antibodies 
that neutralise a large amount of tier 1 and tier 2 HIV-1 viruses as those viruses are 
most prevalent [127]. HIV-1 infected patients with broadly neutralising sera are found 
to produce anti-gp120 CD4bs site antibodies more than antibodies targeting other 
regions. Because of the conservation of the CD4bs sequence and the accessibility of 
the epitope by antibodies, it may be profitable to create immunogens with high 
structural and chemical similarity to the CD4bs epitopes for vaccine purposes. The 
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current array of anti-CD4bs antibodies also provide one with a scaffold for designing 
anti-gp120 antagonist [128-134]. 
Walker et al (2010) assessed the serum neutralising antibody specificities in non-
clade B carriers of HIV. All the patients studied had displayed strong, broad and 
potent serum neutralising activity against recombinant gp120 (rgp120) and trimeric 
gp140. One third of the patients had unidentifiable neutralising specificity; however it 
is presumed that those neutralising antibodies target quaternary structural epitopes 
of env trimers [135]. A group of patients had antibodies recognising recombinant 
trimeric gp140 much better than rgp120 indicating that those antibodies are more 
efficient at targeting a trimeric gp120 foldon than single rgp120 or that they recognise 
gp41 epitopes. It was also presumed that the recognition efficacy of epitopes by 
these antibodies would vary amongst isolates and trimeric gp140 foldons. Even 
though 30% of the donors participating in the study had sera containing antibodies 
that target the membrane-proximal external region (MPER), these antibodies did not 
considerably affect the overall activity of the sera [128, 129, 135]. The data 
suggested that antibodies targeting the MPER are rare and not generated in large 
amounts compared to antibodies that target other regions. Predominantly, broadly 
neutralising monoclonal antibody (bnMAbs) that target the CD4-binding site (CD4bs) 
and CoRbs are most abundant in the donor serum [128, 135]. Donors displaying 
serum with low neutralisation breadth and activity may have numerous antibody 
types of varying specificity, while some donors have fewer antibody types and less 
specificity, but with great neutralisation breadth and potency [129, 135, 136]. 
Moreover, some patients have different antibodies that target the same or 
overlapping epitope and their sera generally provide greatest neutralising breadth 
and potency. Twenty one percent of antibodies generated amongst donors targeted 
either the same or overlapping epitopes of those of monoclonal antibody PG9 and 
PG16, 26% of serum antibodies targeted the N-glycan of residue 332 of Env, 26% of 
antibodies targeted the CD4bs and/or CoRbs and another 21% of the antibodies 
were sensitive to the I165A mutation of env. Interestingly, the remaining 6% of 
antibodies generated were directed at unknown (cryptic) epitopes, presumably 
arising from quaternary structures of full length env trimers [135]. Another strategy 
that may be employed is identifying cryptic, conserved epitopes and finding ways to 
elicit antibodies against those epitopes [137]. 
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It has been shown that priming the immune systems of non-human primates with 
neutralizing antibodies may have a protective effect against HIV acquisition (passive 
immunisation) [138-140]. Alternatively, the neutralising antibodies may be used as 
templates to generate molecules with enhanced anti-HIV activity. A large number of 
antibodies have been found to be elicited after infection with HIV which target 
conserved and variable regions of HIV envelope protein [128]. Some antibodies are 
capable of neutralising HIV from many different subtypes and are referred to as 
broadly neutralising monoclonal antibodies (bnMAbs). It is unknown when bnMAbs 
will be developed by patients and which regions of env they would target. It is 
predicted that after approximately 2.5 years post HIV infection, bnMAbs are 
generated and in some case just after 1 year. If the patient does not generate 
bnMAbs within 2 years of infection, it is unlikely that they will generate bnMAbs [135]. 
The bnMAbs generated target conserved motifs of env such as the CD4bs of the env 
trimers [117, 120, 141]. It is unclear, however, why some antibodies show limited 
neutralising potential for various strains and why others are broadly neutralising 
[142].  
The angle of recognition is one factor which may determine how potent two 
antibodies, with the same epitope will be, if they have different neutralization breath 
[14, 116, 117]. Notably, antibodies that recognize more variable regions of env may 
be rendered ineffective after some time as the variable regions increase in length or 
gain mutations due to viral evolution. These antibodies, targeting variable regions, 
are usually generated early on in infection, but they have limited neutralising capacity 
compared to those antibodies in late infection [135]. Patients who generate 
antibodies to variable regions of env are more susceptible to viral escape than those 
having antibodies that target conserved regions [143].  Recently, bnMAbs that target 
variable regions and show great potency have been discovered. These antibodies 
which target quaternary env epitopes of HIV display comparable efficacy to 
antibodies targeting the CD4bs [113, 135, 144-147]. 
 
31 
 
1.7.3.1 Antibody IgG1 b12 
Understanding how anti-HIV antibodies are elicited by the body will improve vaccine 
design initiatives. As highlighted before, it is observed that most anti-HIV antibodies 
which are elicited by patients recognize conserved regions of env. One of the 
antibodies that recognize the CD4 binding site of gp120 is antibody b12 which was 
isolated from the bone marrow of a patient who was asymptomatic but seropositive 
for 6 years [148, 149]. When tested against a variety of HIV strains belonging to 
subtype B, b12 was shown to neutralize 75% of the strains, it also reacted with more 
than 50% of strains belonging to subtypes A-D and one strain of subtype E [149]. 
Passive immunization of human peripheral blood leukocytes in severe combined 
immunodeficient mice (hu-PBL-SCID) with b12 can protect these mice from viral 
challenge even several hours post treatment [150]. The global structure of b12 is 
asymmetric; it has an 18 amino acid long CDR H3 region with a tryptophan residue 
at the tip [120]. According to the crystal structure of gp120 in complex with b12, b12 
targets the outer domain of gp120 like CD4, but also contacts V1 and V3 regions of 
gp120, thus allowing it to neutralize approximately 40% of all known HIV-1 subtypes 
[120, 148, 151, 152]. Other anti-CD4bs antibodies or agents may act as CD4 
analogues, binding in such a way as to permit gp120 to refold and expose its co-
receptor binding site [6, 153-156]. Antibody b12, however, does not allow gp120 to 
reveal its co-receptor binding site after binding [157]. Notwithstanding the breadth 
and potency of neutralization displayed by b12, more efficacious CD4bs bnMAbs are 
being discovered.  
 
1.7.3.2 Antibody F105 
Antibodies F105 and b12 target overlapping epitopes; however the degree of 
neutralisation between them differs [14]. Antibody b12 neutralises a wider panel of 
HIV-1 strains and more potently. Both F105 and b12 have relatively long 
complementary determining region (CDR) H3 regions, but that of b12 is longer 
consisting of 18 residues compared to F105 with 15 residues [158-160]. The longer 
length of b12 CDR H3 region may account for its better neutralising capacity as it 
accesses the hydrophobic CD4 binding pocket deeper than the F105 CDR H3. 
Unlike b12, F105 has an apical CDR H3 phenylalanine 100A residue that accessed 
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the CD4bs much like phenylalanine 43 of CD4. Antibody b12 uses an apical CDR H3 
tryptophan 100A to access the CD4 phenylalanine 43 binding pocket instead [160]. 
F105 binds to the CD4bs of gp120 with its heavy chain residues in a similar way to 
CD4. In fact, arginine 59 of CD4 and arginine 100F of F105 both interact with 
aspartic acid 368 of gp120 analogously [14]. The CD4 and F105 bound states of 
gp120 are highly similar; overlaying CD4 bound or F105 bound states of gp120 
provides an RMSD of approximately 1.97 angstroms (Å). B-cells generating b12 
have undergone more affinity maturation (by somatic hypermutation) than those 
producing F105, evident in the greater amount of germ-line V and J region mutations 
experienced by b12 producing B-cells (F105 has 13 mutations whereas b12 has 45 
mutations) [160]. 
 
 
1.7.3.3 Antibody HJ16 
An antibody molecule that provides similar breadth of neutralisation and activity to 
antibody b12 against HIV is HJ16 [126, 129]. Unlike antibody b12, HJ16 was isolated 
from a patient infected with HIV of clade C. Antibody HJ16 neutralises approximately 
one third of all HIV-1 virus and targets the region proximal to the CD4bs [129]. 
Interestingly, HJ16 selectively neutralises multiple tier-2 pseudoviruses, making it a 
candidate employable for vaccine design strategies. It has been shown to inhibit the 
binding of soluble CD4 (sCD4) to HIV gp120, but shows incomplete inhibition of 
antibody b12 to gp120. HJ16 and b12 are found to recognise non-overlapping, 
discontinuous epitopes of the CD4bs which are proximal to each other [126, 129]. 
Other CD4bs antibodies along with b12 are unable to neutralise D368R gp120 
mutants, however the mutation does not affect the activity of HJ16 making it a viable 
option for viruses resistant to most anti-CD4bs antibodies. Moreover, the D368R 
gp120 mutants are bound more tightly by HJ16 compared to wild-type gp120 [14, 
129, 151]. 
 
1.7.3.4 Antibody VRCO1 
Another antibody that recognizes the CD4 binding site (CD4bs) of gp120 is VRC01. 
No other known antibody shows more potency and breadth in neutralisation than 
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VRC01, which neutralises 91% of HIV-1 subtypes. Using computer-assisted protein 
design, recombinant env probes were generated to specifically identify CD4bs 
antibodies from a population of B-cells [116, 117, 141]. Wu et al (2010) successfully 
isolated a somatic variant of VRC01 and named it VRC02 as well as a unique IgG1 
clone named VRC03 using the same computer-assisted protein design strategy 
[141]. Interestingly, VRC01 and VRC02 have identical CDR H3 sequences and both 
are highly somatically mutated. Compared to the putative germ-line sequences, 
VRC01 and VRC02 nucleotide sequences are 32% divergent in the variable heavy 
encoding (VH) region and 17-19% in the variable kappa encoding (VK) region. Much 
of VRC01 neutralisation success is based on its ability to mimic the binding of CD4 
to gp120. B-cells producing VRC01 have undergone extensive affinity maturation 
processes to enhance the binding capacity of the VRC01 to gp120, evident in the 
unique structure of the antibody [116]. Crystal structural data shows the structures of 
gp120 post VRC01 or CD4 binding are almost identical, deviating from each other 
minimally [117]. In spite of the great activity of VRC01 against HIV-1, the env probes 
used to generate the antibody were modified to have residues homologous to SIV 
gp120 and some residues not related to gp120 sequences. The probes also had 
variable regions 1 and 3 regions removed, so it is unclear how the variable regions of 
gp120 would affect the actions of VRC01, 2 or 3 [116, 117]. It remains to be seen if a 
patient can generate VRCO1-like antibodies, independently, with similar potency to 
env trimers.  
 
1.7.4 Molecular mimics of cell-surface CD4 to prevent viral entry 
Considering that HIV generally requires CD4 for virion attachment to host cells, 
molecules that resemble cell-surface CD4 (structurally and chemically) would 
compete for binding to gp120 protein and reduce the amount of virus attaching to 
host cells [153, 161-167]. Molecular mimics of cell-surface CD4 such as recombinant 
2dsCD4 or 4dsCD4 do not have a transmembrane peptide and cytoplasmic tail and 
have been used as immunotherapeutic agents against HIV infections. These soluble 
versions of CD4 behave as ‘molecular decoys’, because they have the ability to 
mimic the CD4-gp120 interaction, disrupt the non-covalent associations of env 
subunits and cause the premature shedding of virion env proteins [164, 165, 168-
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181]. The differences in activity between 2dsCD4 and 4dsCD4 against HIV are 
negligible, because domains 3 and 4 of CD4 or 4dsCD4 do not contribute 
significantly or directly to gp120 binding [182]. Both forms of soluble CD4 have the 
gp120-binding amino-terminal domain 1 of CD4 (amino acids 1-92) which shares 
32% homology with immunoglobulin variable regions and domain 2 which is 
intimately associated [183].  
Several groups have described targeting HIV-1 by using recombinant, soluble CD4-
based therapies [171, 173-177, 184-191]. Ongoing research in the field aims to 
discover new ways of generating the CD4-based therapies and improving their 
pharmacokinetic properties. 
 
1.7.4.1 Recombinant soluble CD4-immunoglobulin fusion 
molecules 
Soluble CD4 portions were genetically fused to IgG1 and IgM constant portions to 
block HIV infectivity and reduce syncytia formation [162, 163, 182, 192]. Arthos et al 
(2002) later improved the avidity of CD4-IgG1 by creating polymeric fusions thereof 
[193]. A large number of CD4-immunoglobulin fusion variants have been described 
with different effector functions and avidity levels [153, 162, 165, 166, 168, 193-195].  
Allaway et al (1993) and have shown that a smaller bivalent CD4-γ2 fusion protein 
can act synergistically with drugs that target other regions of gp120 and prevent HIV-
1 mediated cell fusion [196]. It is predicted that patients who are capable of 
producing antibodies against the V3 region of gp120 and gp41 subunits would 
therefore have an enhanced ability of neutralizing HIV-1 when supplemented with a 
CD4-based immunotherapeutic. Syncytia formations have been found to catalyse the 
spread of HIV-1 virions between uninfected and infected cells. To this end, 
combination therapies that incorporate CD4-based molecules and other entry 
inhibitors would considerably reduce HIV infection of host cells, syncytia formation 
and delay the onset of AIDS [119, 153, 196-198]. 
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1.7.4.2 PRO 542 
PRO 542 (CD4-IgG2) is a chimeric molecule composed of two-domain soluble CD4s 
(2dsCD4) attached to the Fc and light chain kappa portions of human IgG2 (Figure 
1.4). PRO 542 is able to bind to the discontinuous CD4bs epitope of gp120 which 
naturally recognizes cell-surface CD4 [153, 181, 196, 199]. In comparison with 
2dsCD4 or 4dsCD4, PRO 542 is significantly more effective in neutralizing HIV-1 
plasma, ex vivo, and can also neutralize T-cell line-adapted viruses and primary 
isolates of HIV-1 [6, 153, 200-205]. The tetrameric PRO 542 resembles naturally 
occurring antibodies structurally, due to the soluble CD4 moieties having 
immunoglobulin-like structure [6, 153]. To date, there is no crystal structural 
information showing the full structure of PRO 542 or PRO 542-gp120 complexes. 
When observing immunoelectron microscopy images of PRO 542-HIV complexes, 
however, one may identify four irregular shaped lobes around a smaller structure. 
The lobes are presumed to be gp120 and the centre structure being an Fc portion of 
PRO 542. Therefore, one PRO 542 molecule has the capacity to bind to four gp120 
molecules as it has four 2dsCD4 domains that contain gp120 binding sites which 
extend flexibly into the solvent environment [6, 153, 196-200, 204].  
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Figure 1.4: The structure of PRO 542. The structure of PRO 542 (CD4-IgG2) was 
obtained from Allaway et al (1995) [153]. 
 
The human IgG2 Fc portion plays a number of structural and functional roles in PRO 
542 molecules. Structurally; the Fc portion acts as a scaffold that holds the 2dsCD4 
moieties in relatively close proximity to each other and allows increased potential of 
the tetrameric molecule to bind more than one gp120 molecule [6, 119, 153, 162, 
166, 199]. Functionally; the Fc portion reduces the rate of the 2dsCD4 catabolism in 
the human body, thus extending the half-life of 2dsCD4 moieties by three to four 
days, compared to minutes without the Fc portion [153, 166, 181, 196, 199, 202, 
206-208]. Depending on the Fc portion used, one may change the type antibody-
dependent cell-mediated cytotoxicity (ADCC) against HIV or other immune effector 
responses [162, 163, 199]. Another benefit of attaching 2dsCD4 moieties to IgG2 Fc 
portions is the potential transfer of immune responses between mother and foetus 
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using Fc dependent receptors (passive immunity via the transcytosis mechanism) 
[162, 166, 199]. The high affinity Fc receptor 1 (FcR1) binds monomeric IgG as well 
as antigen-IgG complexes. Although FcR1 interacts with IgG isotopes 1, 3 and 4, it is 
inert to IgG2. The low affinity FcR2, however, does interact with IgG2, but not as 
efficiently as it does with IgG1 or 3 [199, 209].  
 
PRO 542 displayed cross-clade neutralization of HIV-1 and is more effective than 
some human monoclonal antibodies (huMabs) in neutralizing primary HIV-1 isolates 
[198, 202, 205]. All HIV-1 subtype B primary isolates were neutralized by PRO 542 
with a median IC50 of 6.2 µg/mL, but non-subtype B viruses that were tested were 
more susceptibility to neutralization, having a median IC50 of 4.8 µg/mL [198, 205].  
One human monoclonal antibody (huMab) tested alongside PRO 542, IgG1 b12 
which binds to an epitope overlapping that of PRO 542 in the CD4 binding site of 
HIV-1, showed lower cross-neutralizing activity than PRO 542 [198]. A separate in 
vivo study, using the human peripheral blood leukocyte severe combined 
immunodeficient (hu-PBL-SCID) mouse model injected with peripheral blood 
mononuclear cells (PBMCs) and HIV-1 showed that PRO 542 can reduce HIV-1 viral 
loads in animal models. On average, HIV-1 titres were lowered by 5- to 625-fold 
when PRO 542 was administered to the infected SCID-mouse. At a dose level of 10 
mg/kg, four out of six mice tested, were effectively protected from HIV-1JR-CSF, but 
were vulnerable to HIV-1AD6. The dose levels of PRO 542 were then increased 5-fold 
and four of the five mice were protected from HIV-1JR-CSF and HIV-1AD6 [197]. 
 
In phase 1/2 clinical testing involving paediatrics of different race and gender, PRO 
542 showed impressive pharmacokinetics in HIV-1 neutralization, as well as low 
toxicity to patients. PRO 542 was the primary contributor of reduced viral loads in the 
tested patients [153, 197, 198, 201, 204]. An adult cohort with variable demographics 
was also treated with PRO 542 and they also did not show adverse side effects from 
PRO 542 infusions, at all doses tested. PRO 542 was not found to react with any 
other epitopes on the virion surface besides the CD4bs. High anti-viral activity was 
achieved by PRO 542 as marked decreases in HIV RNA and plasma viremia were 
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detected. One patient who was infused with 10 mg/kg of PRO 542 showed greater 
than 2 log reduction in HIV RNA level 2 weeks post-infusion. It was hypothesised 
that such rapid clearance of PRO 542 coated virus was attained by the 
reticuloendothelial system. Although the Fc portion of PRO 542 has limited effector 
function, it is believed that its ability to opsonise virus by cross-linking may increase 
the clearance of virus efficiently. PRO 542 was, however, discontinued from clinical 
trial after the log drop in patient viral load was not significant enough to warrant 
further human clinical trials. [82, 153, 197, 200, 202, 210]. 
When patients were infused with PRO 542 and T-20 (Enfuvirtide), synergistic 
neutralization of HIV-1 was achieved, which countered the multi-step entry 
processes of HIV-1 [82]. T-20 is unable to recognize its gp41 epitope before gp120 
has attached to cell surface CD4, but can bind transiently exposed gp41 pre-fusion 
intermediates. PRO 542 can cause viral env shedding and exposure of gp41 
epitopes, allowing it to work collaboratively with T-20 and consecutively in preventing 
viral attachment and fusion. Both drugs are individually capable of neutralizing a 
broad range of genetically diverse strains of HIV-1 as they bind to conserved regions 
of gp120 that are imperative for viral attachment and entry. Due to the potency of the 
synergy between PRO 542 and T-20; lower doses of the drugs may be employed in 
synergistic combination therapies compared to monotherapy, thus reducing drug 
toxicity in patients [82, 119]. PRO 542 and other CD4-based therapies are good 
templates for the design of gp120 CD4bs antagonists [196, 199]. 
 
1.7.4.3 Chalcogen substitutions in 2dsCD4  
Cerutti et al (2010) showed that introducing a cysteine residue in the vicinity of a 
gp120 disulphide may increase the affinity and avidity of CD4 for gp120. By 
substituting CD4 serine 60 with a cysteine residue, a CD4 thiol group interacts with 
the gp120 disulphide C126-196C by virtue of a redox-exchange reaction. Unlike wild-
type 2dsCD4 which binds to gp120 non-covalently, the 2dsCD4S60C binds covalently 
to gp120 and may reduce the potential of gp120 dissociating from CD4 [180]. We 
hypothesize that the addition of the S60C mutation to a CD4-IgG2 protein will bind 
HIV-1 gp120 covalently, thereby increasing the molecules therapeutic potential. This 
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study details the development of a wild-type CD4-IgG2 protein as well as a S60C 
mutant CD4-IgG2 protein, which is intended to bind more tightly to HIV gp120 than 
the wild-type protein.  
 
1.8 Aims of the study 
The overall aim of this study was to construct a modified PRO 542-like fusion protein 
containing the D1D2 domains of CD4 and an IgG2 Fc portion and compare it to wild-
type PRO 542 (PRO 542wt) in its ability to bind HIV-1 gp120. The ‘mutant’ PRO 542 
(PRO 542mt) would be designed based on the patented chalcogen substitution 
(patent: PCT/IB2009/051287, described in section 1.7.4.3) to bind to HIV-1 gp120 
covalently. The chalcogen substitution in the D1D2 CD4 domains of PRO 542mt is 
expected to increase the bond strength between the PRO 542mt and HIV-1 gp120. If 
the PRO 542mt proves to have superior binding and activity against HIV-1 gp120, it 
would warrant further preclinical investigation as an attachment inhibitor. 
This was achieved by the following objectives: 
1.8.1. To construct mammalian expression vectors, each containing cDNA inserts 
which encode for heterotetrameric kCD4-IgG2wt (PRO 542wt) and kCD4-IgG2S60C 
(PRO 542mt) chains. 
1.8.2. To express and purify the heterotetrameric kCD4-IgG2wt and kCD4-IgG2S60C 
recombinant proteins. 
1.8.3. To characterize and compare the biochemical activities (binding specificity) of 
heterotetrameric kCD4-IgG2wt and kCD4-IgG2S60C against HIV-1 gp120. 
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Chapter 2: Materials and Methods 
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2.1 Reagents used in this study. 
All reagents obtained through the NIH AIDS Research and Reference Reagent 
Programme, division of AIDS, NIAIDS, and NIH (https://www.aidsreagent.org) are 
listed in Table 2.1.  
The CD4-IgG2 (PRO 542) protein was used as a positive control in sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE)/Western blot analyses and 
surface plasmon resonance (SPR) binding experiments. The recombinant HIV-1CN54 
gp120 (gp120 CN54), HIV-1SF162 gp120 (gp120 SF162) were available from the NIH 
AIDS Research and Reference Reagent Programme (Table 2.1), whereas HIV-
196ZM651 gp120 (gp120 ZM), HIV-1Bal gp120 (gp120 Bal), HIV-1IN25925 gp120 (gp120 
IN) and HIV-1ZA706010164 gp120 (gp120 ZA) were available in our laboratory. All 
recombinant gp120 were used as ligands in SPR experiments. Two-domain CD4 
(2dsCD4wt) and two-domain CD4 S60C mutant (2dsCD4S60C) were available in our 
laboratory and used as positive controls in SPR experiments. Monoclonal antibody 
17b (MAb 17b) was used to confirm the exposure of CD4 induced epitopes (CD4i) in 
SPR experiments. The HIV-193TH975 gp120 (gp120 93TH975) and gp120 Bal were 
used as positive controls in immunoprecipitation experiments. The Chessie 13-39.1 
(Chessie) supernatant, ID6 and NEA-9301 anti-gp120 antibodies (Perkin Elmer; 
Waltham, Massachusetts) were used as the primary antibodies in Western blotting 
for gp120 protein detection in immunoprecipitation experiments. The anti-CD4 
antibody (clone MT310; Santa Cruz Biotechnology INC; California, USA) was 
used as a primary antibody and an anti-mouse Ig horseradish peroxidase-linked 
whole antibody (GE Healthcare; Buckinghamshire, England) was used a 
secondary antibody in all Western blotting experiments. The pCI-neo mammalian 
expression vector with an insert encoding four-domain soluble CD4 with an S60C 
mutation (4dsCD4S60C) (p4dsCD4S60C) used for single transfection optimization was 
available in our laboratory. Monomer solution and TEMED used in SDS-PAGE 
were purchased from Sigma-Aldrich (St. Louis, USA). 
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Table 2.1 All the reagents obtained from the NIH AIDS Research and Reference 
Reagents programme used in this study. 
Catalogue 
Number 
Name of reagent Source 
4091 Antibody 17b Dr. James E. Robinson 
11780 CD4-IgG2 (PRO 542) Progenics Pharmaceuticals 
7749 HIV-1 CN54 gp120 Dr. Ian Jones 
7363 HIV-1 SF162 gp120 DAIDS, NIAID 
990 Chessie 13-39.1 supernatant Dr. George K. Lewis 
2343 Antibody ID6 Dr. Kenneth Ugen and Dr. David 
Weiner 
3234 HIV-1 gp120 93TH975 BioMolecular Technology 
 
 
2.2 Computer-modelling of the gp120-2dsCD4 interaction 
Previous studies conducted in our laboratory showed that mutating CD4 serine 60 to 
cysteine allows the introduction of a thiol group within the vicinity of the gp120 126C-
196C disulphide, which allows for a stabilized inter-molecular redox exchange 
reaction to occur [106, 180, 211]. The crystal structure coordinates of gp120 in 
complex with CD4 and antibody 17b were obtained from the Protein Data Bank 
(PDB), PDB ID 1G9M [106]. The structures were viewed using the PyMOL Molecular 
Graphics System, evaluation version 1. 2. 8, Schrodinger, LCC and Swiss PDB 
viewer (version 4.0.4) [211].  
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2.3 Design of kCD4-IgG2wt and kCD4-IgG2S60C encoding recombinant plasmids. 
A total of four constructs were designed to generate a wild-type (wt) and mutant 
S60C tetravalent chimeric antibody, consisting of four two-domain soluble CD4 
(2dsCD4)-like moieties grafted onto an IgG2 scaffold (Figure 2.1 A). The wild-type 
chimeric antibody (kCD4-IgG2wt) heavy chain (HC) gene sequence was similar to 
that of the PRO 542 HC sequence (ATCC no. 75193). It contained all the exons 
coding for the human CD4 leader/signal sequence and the first two domains of 
human CD4 (amino acids 1-179) fused to the Fc portion of human IgG2, but 
excluded all the introns.  Similarly, the kCD4-IgG2wt light chain (LC) gene sequence 
was identical to that of the PRO 542 LC sequence (ATCC no. 75194) and contained 
all the exons coding for the human CD4 leader/signal sequence and the first two 
domains of human CD4 (amino acids 1-179) joined to the first codon of the constant 
portion of the human IgG2 kappa LC sequence (Figure 2.1 A) [199]. The constructs 
composed of kCD4-IgG2wt HC and LC cDNA cloned into pcDNA 3.1 (+) were called 
pKHwt and pKLwt, respectively. The mutant kCD4-IgG2S60C HC and kCD4-IgG2S60C 
LC encoding constructs (pKHS60C and pKLS60C) were identical to the wild-type 
constructs with the exception of a serine to cysteine mutation at position 60 of the 
CD4 portions.  The four constructs were ordered from GeneArt (Regensburg, 
Germany), and cloned into pcDNA3.1 (+) (Invitrogen; Figure 2.1 B). 
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i:     ii   
Figure 2.1 A: The structure of kCD4-IgG2wt and kCD4-IgG2S60C. The images 
numbered with Roman numerals 1 and 2 display the structure of kCD4-IgG2wt and 
kCD4-IgG2S60C, respectively. In both images, the green ovals represent the domains 
of 2dsCD4; the yellow ovals represent the constant light chain kappa regions of 
IgG2; the red ovals represent the CH1 domain of IgG2; the pink ovals represent the 
hinge region of IgG2; the blue ovals represent the CH2 regions of IgG2; the orange 
ovals represent the CH3 regions of IgG2 and the black lines represent interchain 
disulphide binds. In the image of kCD4-IgG2S60C, the black stars show the 
approximate location of the serine to cysteine mutation at residue position 60. 
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Figure 2.1 B: The pcDNA 3.1 (+) vector (5428 bp) used to express the chains of 
kCD4-IgG2wt or kCD4-IgG2S60C. The cDNA sequences of the recombinant proteins 
were cloned into the mammalian expression vector using BamH1 and Eco R1 
restrictions sites. 
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2.4 Transformation of E. coli DH5α cells with pcDNA 3.1 (+) constructs. 
Upon arrival from GeneArt, the four lyophilized recombinant constructs were 
resuspended in sterile distilled water (dH2O) to a concentration of 0.25 µg/µL. 
Chemically competent Escherichia coli (E. coli) DH5α cells (available in our 
laboratory) were removed from -80 °C storage conditions and allowed to thaw on ice. 
Ten microlitres of each recombinant construct were added to separate 100 µL 
aliquots of E. coli DH5α cells and placed on ice for 30 minutes. Thereafter, the 
bacterial cells were heat shocked for 90 seconds at 42 °C and then placed 
immediately on ice. The now transformed bacterial cells were then provided with 100 
µL of LB broth (Appendix 1.1) and shaken at 250 rpm in a 37 °C incubator for 1 hour. 
After incubation, the bacterial cells were plated out onto LB agar plates (Appendix 
1.2) with 10 µL of ampicillin (Merck; Darmstadt, Germany; Appendix 1.3) at a 
concentration of 100 µg/mL.  The plates were then incubated at 37 °C for 24 hours. 
 
2.4.1 Glycerol stocks production 
A single colony of transformed bacterial cells was isolated from LB agar plates 
(Appendix 1.2), inoculated into 50 mL LB broth containing 1X of ampicillin (Appendix 
1.3) and incubated in a 37 °C incubator on an orbital shaker at 250 rpm for 16 hours. 
Thereafter, aliquots of 800 µL cultured transformed bacterial cells were added to 200 
µL of glycerol (Saarchem, South Africa) and these were stored in a -80 °C freezer for 
long-term storage. Before use, the aliquots were thawed on ice to 4 °C. 
 
2.4.2 Plasmid preparation, isolation and purification 
Glycerol stocks of transformed bacterial cells (harbouring one of the recombinant 
constructs) (refer to 2.4.1) were thawed on ice for 20 minutes. Ten µL of cultured 
transformed bacterial cells were then added to 500 mL of sterile LB broth with 1 g of 
ampicillin (Merck, Darmstadt, Germany; Appendix 1.3) and shaken in a 37 °C 
incubator at 250 rpm for 16 hours. The bacterial culture was then centrifuged at 6000 
rpm and 4 °C for 20 minutes using an Avanti J-E centrifuge (Beckman Coulter; 
California, USA). To extract the recombinant plasmid from the bacterial cells, a 
Qiafilter Maxi Prep Plasmid Kit (Qiagen; Venlo, Netherlands) was used according to 
the manufacturer’s instructions. In brief, the bacterial pellet was homogenously 
resuspended in 10 mL of buffer P1 (containing 1 mg/mL of ribonuclease), before 10 
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mL of buffer P2 was added to lyse the cells under alkaline conditions. The resulting 
mixture was inverted six times and allowed to incubate at 20 °C for 5 minutes. 
Following that, 10 mL of Buffer P3 was added and the mixture was inverted another 
6 times to neutralise the cells and lysate. The lysate and cells were then transferred 
to a Qiafilter cartridge (provided in the kit) and allowed to incubate for 10 minutes at 
20 °C. To separate the lysate from the cells, a plunger was inserted into the Qiafilter 
cartridge, allowing the lysate to filter out from the cells. The lysate was collected in a 
Qiagen-tip (provided in the kit), which was previously equilibrated with buffer QBT to 
commence gravity-flow anion-exchange chromatography. Once the lysate had 
entered the Qiagen-tip resin; proteins, RNA and genomic DNA were washed out 
using buffer QC and the plasmid DNA was eluted using buffer QF. To precipitate the 
plasmid DNA from the elution, 0.7 volumes of 70% isopropanol (Appendix 1.8) was 
added and the mixture was centrifuged at 4000 rpm for 1 hour and 4 °C using an 
Eppendorf centrifuge 5810 R (Eppendorf; Hamburg, Germany). The resultant 
supernatant was discarded whilst the pelleted plasmid DNA was washed with 70% 
ethanol (Appendix 1.9). The plasmid DNA was pelleted out by centrifugation at 4000 
rpm for 1 hour and at 4 °C using the Eppendorf centrifuge 5810 R (Eppendorf; 
Hamburg, Germany).  The resultant supernatant was discarded and the plasmid 
DNA was allowed to air-dry for 1 hour before being resuspended in 500 µL of sterile 
dH2O. The amounts and purity of plasmid DNA collected were determined using a 
Nanodrop ND1000 spectrophotometer (Thermo Fisher Scientific; Massachusetts, 
USA).  
 
2.5 Agarose gel electrophoresis 
The purity, homogeneity and size of the constructs were assessed using agarose gel 
electrophoresis.   One microlitre of ethidium bromide (Promega; Madison, USA) at a 
concentration of 10 mg/mL was dissolved in 100 mL of a 0.7% agarose gel 
(Appendix 1.11). One microlitre of each purified construct was diluted with 5 µL 6X 
loading buffer (Appendix 1.12) before the mixture was loaded in the well. The 
O’GeneRuler DNA ladder mix (Fermentas, Massachusetts, USA) was run as a 
molecular weight standard. Electrophoresis of the samples was conducted at 77 V 
using a Bio-Rad powerpack (Bio-Rad laboratories, Hercules, USA) for 2 hours.  The 
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agarose gel was subsequently visualised by UV light, using a UV 
transilluminescence machine. 
 
2.5.1 Characterization of recombinant plasmids (Plasmid DNA digestion 
with Eco R1) 
Each of the four recombinant plasmids was characterized by restriction enzyme 
digestion to ensure they were of the correct size. One µL of each purified 
recombinant plasmid (refer to 2.4.2) was placed in a separate reaction tube 
containing 2 µL of Eco R1 supporting buffer (Fermentas; Massachusetts, USA), 1 µL 
of Eco R1 (Fermentas, Massachusetts, USA) at a concentration of 10 U/µL and 14 
µL of sterile double deionised H2O (ddH2O). The four reaction tubes were then 
incubated in a 37 °C water-bath for 1 hour and 30 minutes to catalyse the reactions. 
The reaction was stopped by placing the reaction tubes on ice.  Thereafter, a 5 µL 
sample from each reaction tube was analyzed by agarose gel electrophoresis (see 
section 2.5). 
 
2.6 Optimization of recombinant protein expression in Human Embryonic 
Kidney 293T cells (HEK293T) 
 
2.6.1 HEK293T mammalian cells 
2.6.1.1 Feeding and passaging of HEK293T mammalian cells 
HEK293T cells (available in our laboratory) were grown in 75 cm3 dishes (Thermo 
Fisher Scientific; Massachusetts, USA) in 14 mL of Dulbecco’s Modified Eagle 
Medium (DMEM) (Sigma-Aldrich; St. Louis, USA) supplemented with 10 mM 
Glutamax™ L-glutamine (Invitrogen; California, USA) and 10% fetal bovine serum 
(FBS) (Sigma-Aldrich, St. Louis, USA) (complete DMEM) in a 37 °C and 5% CO2 
incubator. Once the cells had grown to 80% confluence; the culture supernatant was 
discarded and the adherent cells were rinsed with 10 mL of 1X phosphate buffered 
saline (PBS) (Sigma-Aldrich; St. Louis, USA) and split by incubating them with 500 
µL of 0.25% trypsin: EDTA mix (Sigma-Aldrich; St. Louis, USA) for less than five 
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minutes at 37 °C. The trypsin: EDTA solution was then discarded and 10 mL of fresh 
complete DMEM was added to the cells. Cells were split ten-fold and placed into 
new tissue culture flasks with appropriate amounts of fresh complete DMEM. Once 
the cells had been passaged twenty times, they were discarded and replaced with 
thawed cell stocks. 
 
2.6.1.2 Preparation of HEK293T frozen cell stocks and thawing 
Split cells were supplied with 10% dimethyl sulphoxide (DMSO) (Fluka chemika; 
Buchs, Switzerland) in fresh complete DMEM. The cells were stored at -80 °C and 
thawed on ice before use. 
 
2.6.1.3 Quantification of HEK293T mammalian cells 
Twenty microlitres of the split HEK293T cells was combined with 80 µL of Hyclone 
trypan blue (Thermo Fisher Scientific; Massachusetts, USA), and placed on a 
haemocytometer (Neubauer, West Germany) slide for counting on an Olympus 
CKX41 microscope (Olympus America Inc; USA).  
To calculate the total number of cells (N): the formula N= (m) (tb) (V) (104) was 
employed where ‘N’ is the number of cells in suspension, ‘m’ is the mean of cell 
counts per 0.1 mm3, ‘tb’ is the correction for the trypan blue dilution, ‘V’ is the volume 
of the original cell suspension in millilitres and ‘104’ is for the volume in the original 
cell suspension in millilitres. 
 
2.6.2 Optimization of transient transfections of HEK293T cells  
For all transfection experiments, HEK293T cells that were 80% confluent were split, 
counted, and seeded at 1.2 X 106 or 3.6 X 106 cells per 25 cm3 or 75 cm3 tissue 
culture flask, respectively in complete DMEM, and incubated overnight in a 37 °C, 
5% CO2 incubator. When the HEK293T cells from the overnight flasks reached 40-
80% confluence, they were ready for use in transfection experiments. 
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Optimal transfection conditions for single and co-transfections were established for 
selected/each construct by testing different DNA concentrations, transfection 
reagents, and post transfection harvest times.  
 
2.6.2.1 Optimization of single-transient transfections of HEK293T 
cells using Lipofectamine™ transfection reagent 
Transfections involving the use of Lipofectamine™ (Invitrogen; California, USA) 
transfection reagent as the DNA carrier were conducted according to the 
Lipofectamine™ Reagent Handbook, in 25 cm3 tissue culture flasks.  
 
Ten micrograms of pKLwt at a ratio of 1 part purified plasmid DNA to 5 parts Opti-
Mem® (µL) (Invitrogen; California, USA) (without additives) was prepared. In a 
separate reaction tube, a ratio of 1 part Lipofectamine™ (Invitrogen; California, USA 
1 µg DNA: 1 µL Lipofectamine™) to 5 parts Opti-Mem® (µL) (Invitrogen; California, 
USA) (without additives) was prepared. The two mixtures were incubated separately 
for 5 minutes at room temperature, combined and incubated for a further 20 minutes 
at room temperature, to allow complex formation. Transfection reagent with no DNA 
added was used as a negative transfection control. 
   
The complete DMEM from the overnight tissue culture flasks was then replaced with 
fresh complete DMEM, and the transfection mix was added to the cells, and 
incubated in a 37 °C, 5% CO2 incubator for up to 48 hours post-transfections. The 
culture supernatant containing the transfection mix was replaced with fresh complete 
DMEM at 16-24 hours post transfection, and kept for SDS-PAGE and Western blot 
analyses (see section 2.6.3). At 48 hours post-transfection, the culture supernatant 
and cells were harvested and stored at 4 °C for subsequent SDS-PAGE and 
Western blot analyses.  
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2.6.2.2 Optimization of single-transient transfections of HEK293T 
cells using different DNA concentrations and Polyfect transfection 
reagent  
Transfections involving the use of Polyfect transfection reagent as the DNA carrier 
(Qiagen; Venlo, Netherlands) were conducted according to the Polyfect Transfection 
Reagent Handbook (Qiagen; Venlo, Netherlands) in 25 cm3 tissue culture flasks.  
 
Two and four micrograms of all the purified recombinant plasmids (section 2.4.2) 
were diluted in 150 µL of DMEM (Sigma-Aldrich; St. Louis, USA; no additives) and 
incubated at room temperature for 5 minutes. Twenty or forty millilitres of Polyfect 
transfection reagent (1 µg DNA: 10 µL Polyfect; Qiagen; Venlo, Netherlands) was 
then added to the 2 µg and 4 µg  DNA solutions, respectively, and incubated for a 
further 20 minutes at room temperature to allow for complex formation. The 
transfection mix was added to the overnight cultures and supernatant and cells were 
harvested and analysed as described in section 2.6.2.1. 
 
2.6.3 SDS-PAGE 
To assess the sizes of proteins expressed after transfections were conducted, a 
discontinuous SDS-PAGE system was employed [212]. A stacking and resolving gel, 
containing 4 and 8.75% acrylamide, respectively, were cast using a Bio-Rad 
system, having a thickness of 1.5 mm each (Hercules, USA). The resolving gel 
solution was poured first (Appendix 2.3) and a thin layer of running gel overlay 
(Appendix 2.3) was applied over it to assist polymerization. Upon completion of 
resolving gel polymerisation, the running gel overlay was decanted. Sterile 
dH2O was used to wash the resolving gel. Stacking gel solution (Appendix 2.3) 
was poured on top of the resolving gel. The height of the stacking gel solution 
poured was twice the height of the volume of sample to be applied.  
All culture supernatant samples were clarified by centrifugation at 3900 rpm, 4 °C 
using an Eppendorf 5810 R centrifuge (Eppendorf; Hamburg, Germany) using 
Amicon® Ultra Centrifugal Filter Units (Millipore, Massachusetts, USA). Clarified 
samples were combined with 2X treatment buffer (Appendix 2.3) in a 1:1 
volumetric ratio to give a final volume of 50 µL, placed in boiling water for 3 
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minutes and loaded into the polymerised stacking gel. NIH PRO 542 was used 
as the positive protein control, unless otherwise stated. The gels were run with a 
constant current of 10 milliamps for approximately 45 minutes, before an 
increased current of 20 milliamps was applied until the dye front had migrated 
to 1 cm from the bottom of the gel.  
 
2.6.4 Western blotting 
Following SDS-PAGE, gels were immersed in transfer buffer (Appendix 2.4) for 
15 minutes and transferred to Hybond-C extra nitrocellulose membrane 
(Amersham Biosciences; Bucks, England) using a Transblot semi-dry transfer 
system (Bio-Rad laboratories, Hercules, USA) with a constant current of 4 
milliamps per gel for 1 hour and 30 minutes. After the transfer process, the 
nitrocellulose membrane was placed in 5% non-fat skimmed milk (Bio-Rad; 
Hercules, USA) dissolved in 1X tris-buffered saline at pH 7.4 supplemented 
with 0.1% tween-20 (1X TTBS) (Sigma-Aldrich; St. Louis, USA (Appendix 2.4)) 
and stored at 4 °C for 24 hours. The nitrocellulose membrane was then rinsed 
with 50 mL of 1X TTBS three times before MT310 antibody (Santa Cruz 
Biotechnology INC; California, USA) at a concentration of 1:1000 in 3 mL was 
applied to the membrane on a flat surface for 1 hour. Following incubation with 
the MT310 antibody, the nitrocellulose membrane was washed with 50 mL of 
1X TTBS three times before anti-mouse Ig horseradish peroxidase-linked 
whole antibody (GE Healthcare; Buckinghamshire, England) at a concentration 
of 1:1000 in 3 mL was applied to the blot on a flat surface for 1 hour.  The 
membrane was washed three times with 50 mL of 1X TTBS to remove any 
unbound antibodies or non-specifically bound antibodies. SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific; Massachusetts, USA) was 
then applied to the membrane according to manufacturer’s instructions. Results of 
this experiment were analysed by monitoring the enzymatic reaction using a 
Chemidoc (Bio-Rad; Hercules, USA) and employing the Chemi-high sensitivity 
setting. 
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2.6.5 Optimization of transient co-transfections for expression of 
heterotetrameric kCD4-IgG2wt and heterotetrameric kCD4-IgG2S60C in HEK293T 
cells 
To determine whether kCD4-IgG2wt HC and LC were able to assemble a fully folded, 
functional heterotetrameric kCD4-IgG2wt protein, the pKHwt and pKLwt plasmids were 
co-transfected into HEK293T cells.  
Co-transfection experiments of varying DNA concentrations with Polyfect 
transfection reagent was performed in 25 cm3, 75 cm3 and 175 cm3 tissue culture 
flasks seeded with 1.2 X 106, 3.6 X 106, or 6 X 106 HEK293T cells, respectively. A 
total of 4 µg (2 µg pKHwt; 2 µg pKLwt LC), 12 µg (6 µg pKHwt; 6 µg pKLwt) and 28 µg 
(14 µg pKHwt; 14 µg pKLwt) of plasmid DNA was transfected into the 25 cm3, 75 cm3 
and 175 cm3 tissue culture flasks, respectively. Transfection controls were flasks 
inoculated with DNA carrier only.  
Sixteen to 24 hours post transfections, the serum containing medium was decanted, 
cells were washed with 1X PBS and supplied with serum-free medium (SFM II) 
supplement with 10 mM of Glutamax™ L-glutamine (both Invitrogen; California, 
USA; complete SFM II).  Every 24 hours for 4 days thereafter, the serum-free 
supernatant was collected (stored at 4 °C) and replaced with the same volume of 
fresh medium. At 96 hours, culture supernatant and cells were harvested and stored 
at 4 °C. All the culture supernatants were then clarified and concentrated using 
Amicon® Ultra Centrifugal Filter Units (Millipore; Massachusetts, USA). Samples 
were analysed by SDS-PAGE and Western Blotting as described in section 2.6.3 
and 2.6.4, respectively.  
 
To determine whether kCD4-IgG2S60C HC and kCD4-IgG2S60C LC were able to 
assemble a fully folded, functional heterotetrameric kCD4-IgG2S60C protein, the 
pKLS60C and pKHS60C plasmids were co-transfected into HEK293T cells grown in 175 
cm3 tissue culture flasks, and analysed as described above.  
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2.7 Large scale expression of heterotetrameric kCD4-IgG2wt and 
heterotetrameric kCD4-IgG2S60C in HEK293T cells  
Culture supernatant from co-transfection experiments of several 175 cm3 tissue 
culture flasks were clarified, pooled, filtered through 0.22 micron filters (Millipore, 
Massachusetts, USA), and used for subsequent purification experiments. Pooled 
supernatant was used immediately or stored at 4 °C. 
 
2.8 Purification of heterotetrameric kCD4-IgG2wt and heterotetrameric kCD4-
IgG2S60C 
Protein-A affinity chromatography was used to purify kCD4-IgG2wt and kCD4-
IgG2S60C from culture supernatants harvested from section 2.7.  
 
2.8.1 Purification of heterotetrameric kCD4-IgG2wt using the Äkta FPLC 
system 
A one-step purification protocol for heterotetrameric kCD4-IgG2wt using a 1 mL 
Hitrap Protein-A HP column (GE Healthcare; Buckinghamshire, England), as per 
manufacturer’s instructions was performed on the Äkta FPLC system (GE 
Healthcare; Buckinghamshire, England). Briefly, the 1mL Hitrap Protein-A HP 
column was equilibrated with 1X PBS (Sigma-Aldrich; St. Louis, USA) at a flow-rate 
of 2 mL/minute for 5 minutes, before the filtered culture supernatant was applied to it 
at a flow-rate of 1 mL/minute. The flow-through was collected, and stored. The 
column was then washed with 1X PBS at a flow-rate of 2 mL/minute for 2 minutes, to 
remove unbound or non-specifically bound material and flow-through was collected. 
To elute the bound proteins, 0.1 M citric acid buffer at pH 3.6 (Appendix 2.7) was 
passed through the column at a flow-rate of 1 mL/minute, and directly collected in 
tubes containing 200 µL of 1 M tris-HCl at pH 9 to neutralize the eluted fraction. 
Absorbance readings at 280 nm were monitored throughout the purification process. 
The UNICORN 5.2 (Build 500) software by GE Healthcare (Buckinghamshire, 
England) was used to monitor the purification steps.  
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The sample flow-through, washes and eluate were each concentrated to 500 µL 
using Amicon® Ultra Centrifugal Units (Millipore, Massachusetts, USA), and 30 µL 
thereof was used for SDS-PAGE and Western blot analysis. 
 
2.8.2 Purification of heterotetrameric kCD4-IgG2wt and heterotetrameric 
kCD4-IgG2S60C using Protein-A agarose beads 
Culture supernatants containing kCD4-IgG2wt or kCD4-IgG2S60C (section 2.7) were 
analysed by SDS-PAGE and Western blot analysis to confirm protein expression, 
and then purified using Protein-A agarose beads (Bio-Rad; Hercules, USA; Appendix 
2.5).  
The Protein-A agarose beads were stored in 1X PBS containing 0.1% sodium 
azide (both from Sigma-Aldrich; St. Louis, USA). Before use, the beads were 
washed thoroughly with 1X PBS without sodium azide. Culture supernatant was then 
incubated with 0.5 mL (kCD4-IgG2S60C) and 1 mL (kCD4-IgG2wt) of washed Protein-
A agarose beads (Bio-Rad; Hercules, USA) (Appendix 2.5) in a 50 mL Nunc tube 
(Roskilde, Denmark), and shaken at 250 rpm at 4 °C for 72 hours.  
To pellet the Protein-A agarose beads with kCD4-IgG2wt or kCD4-IgG2S60C 
adsorbed, the 50 mL tubes were centrifuged at 3900 rpm, 4 °C for 10 minutes using 
an Eppendorf 5810 R centrifuge (Eppendorf; Hamburg, Germany). The supernatant 
was removed and stored at 4 °C.  The beads were then washed by the addition of 1  
bead volume of 0.02 M sodium phosphate buffer at pH 6.5 (binding buffer) (Appendix 
2.6) five times, and centrifuged at 13 000 rpm in an Eppendorf 5415 R centrifuge 
(Eppendorf; Hamburg, Germany) at 4 °C. All subsequent centrifugation steps were 
carried out under these conditions. The resultant washes were pooled, concentrated 
to 500 µL and stored at 4 °C. The elution step involved adding 1 bead volume of 0.1 
M sodium citrate buffer at pH 3.5 (elution buffer) (Appendix 2.7) twice to the washed 
beads. The eluate was immediately transferred to a new reaction tube containing 
200 µL of 1M tris-HCl at pH 9 (Appendix 2.8) to neutralize the elution solution and 
then concentrated to 200 µL before being stored at 4 °C.  
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The beads were subsequently washed with 2 bead volumes of binding buffer 
(Appendix 2.6) and regenerated with 2 bead volumes of regeneration buffer 
(Appendix 2.9). The regeneration flow-through was collected and concentrated to 
500 µL and stored at 4 °C. All solutions were concentrated using the Amicon® 
Centrifugal Filter Units, centrifuged in an Eppendorf 5810 R centrifuge (Eppendorf; 
Hamburg, Germany) at 3900 rpm at 4 °C.  
Thirty microlitres of the initial unbound material, concentrated wash steps, 
concentrated eluate and concentrated regeneration supernatant were each analysed 
by SDS-PAGE and Western Blotting as described in section 2.6.3 and 2.6.4, 
respectively. 
 
2.9 Immunoprecipitation of HIV gp120 with heterotetrameric kCD4-IgG2wt 
To assess whether the expressed kCD4-IgG2wt was fully assembled and had a 
functional CD4 and Fc portion, kCD4-IgG2wt adsorbed to Protein-A agarose beads 
was incubated with purified monomeric HIV gp120 Bal.  
 
 2.9.1 Optimal binding of heterotetrameric kCD4-IgG2wt to Protein-A 
agarose beads   
Varying amounts of kCD4-IgG2wt were incubated with the Protein-A agarose beads 
to identify optimal binding conditions/capacity, and analysed by SDS-PAGE and 
Western blot analysis. Ninety microlitres of beads was washed with 500 µL of 1X 
PBS four times to remove storage buffer (0.1% sodium azide in 1X PBS). Thirty 
microlitre aliquots of the beads were placed in three separate Eppendorf tubes. One 
of the reaction tubes containing 30 µL of beads was incubated with 1 µg of NIH PRO 
542; the second reaction tube containing 30 µL of beads was incubated with 250 µL 
of control supernatant, and the third reaction tube containing 30 µL of beads was 
incubated with  250 µL (approximately 500 ng) of kCD4-IgG2wt containing 
supernatant. The three reaction tubes were then shaken at 250 rpm and 4 °C on an 
orbital shaker for 16 hours. The beads were pelleted using an Eppendorf Centrifuge 
5415 R (Eppendorf; Hamburg, Germany) and the supernatants of the reaction tubes 
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were stored at 4 °C for SDS-PAGE-Western blot analysis as described in section 
2.6.3 and 2.6.4, respectively.  The pelleted beads were washed five times with 1 mL 
of 1X PBS to remove non-specifically bound material.  Beads were analysed using 
SDS-PAGE and Western blotting techniques. NIH PRO 542, gp120 93TH975 and 
gp120 Bal recombinant proteins were included on the SDS-PAGE and Western blot 
as positive controls. The blot was analysed using the MT310 antibody as a primary 
antibody and the anti-mouse Ig horseradish peroxidase-linked whole antibody 
as a secondary antibody. Following that, the blot was stripped, and then had 
the anti-gp120 cocktail (Appendix 2.10) applied to it as a primary antibody and 
the anti-mouse Ig horseradish peroxidase-linked whole antibody as a 
secondary antibody. 
 
Optimal supernatant-bead volumes were used in all subsequent immunoprecipitation 
experiments.  
The Protein-A agarose beads were prepared by washing 150 µL of beads with 500 
µL of binding buffer (Appendix 2.6), pelleting the beads by centrifugation in an 
Eppendorf 5415 R centrifuge at 13 000 rpm and 4 °C and discarding the binding 
buffer supernatant. The wash step was repeated five times before all the beads were 
divided into 50 µL aliquots that were placed in 3 separate Eppendorf reaction tubes 
(Eppendorf; Hamburg, Germany). The three reaction tubes with beads were treated 
with 1 µg of NIH PRO 542 (positive control), 250 µL of the aforementioned 
concentrated kCD4-IgG2wt culture supernatant, or untreated (negative control).  The 
three reaction tubes were then shaken at 250 rpm at 4 °C for 24 hours. The unbound 
materials from the three reaction tubes were kept as the flow-through samples for 
SDS-PAGE and Western blotting analysis. The beads in all the reaction tubes were 
washed with 500 µL of binding buffer 5 times each to remove non-specific binders. 
.  
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2.9.2 Immunoprecipitation of HIV gp120 by heterotetrameric kCD4-IgG2wt  
Two micrograms of HIV gp120 Bal was added to each of the three aforementioned 
reaction tubes (Protein-A agarose beads-kCD4-IgG2wt; bead-NIH PRO 542; beads 
alone) and incubated for 72 hour on a shaker at 250 rpm and 4 °C. The bead-bound 
proteins were then washed with 500 µL binding buffer (refer to appendix 2.6) 5 times 
and pelleted using an Eppendorf 5415 R centrifuge (Eppendorf; Hamburg, 
Germany). Thirty microlitres of the beads, and supernatant (containing unbound 
protein) from each reaction tube were then analysed by SDS-PAGE and Western 
Blotting techniques (refer to 2.7). The primary antibody used in the SDS-PAGE and 
Western blotting analyses was a cocktail of anti-gp120 antibodies (ID6, Chessie 
supernatant and NEA; refer to Table 2.1; Appendix 2.10), whilst the secondary 
antibody used was the anti-mouse Ig horseradish peroxidase-linked whole 
antibody (GE Healthcare; Buckinghamshire, England) as described in section 
2.6.4 (Appendix 2.4). 
 
2.10 Surface plasmon resonance (SPR) studies 
Surface plasmon resonance was used to further characterize the binding of the 
kCD4-IgG2wt and kCD4-IgG2S60C to gp120 using the ProteOn XPR36™ (Bio-Rad; 
Hercules, USA) at 25 °C, with recommended Bio-Rad reagents, unless otherwise 
stated.  
The GLC sensor chip employed for the SPR experiment was pre-conditioned 
by sequentially passing 0.5% SDS, 50 mM NaOH and 100 mM HCl over all 
thirty-six flow cells of the sensor chip at a flow-rate of 30 µL/minute and a 
contact time of one minute. To commence binding studies (activation), a 1:1 
ratio of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-
hydroxysuccinimide (NHS) was mixed and passed over the sensor chip surface to 
activate surface carboxyl groups at a flow rate of 30 µL/minute for a period of two 
minutes.  
The following six recombinant gp120 proteins: CN54, SF162, ZA706010164, 
96ZM651 (ZM), IN25925 (IN) and Bal (Section 2.1) were individually dissolved 
in 10 mM sodium acetate buffer at pH 5.5 to a concentration of 5 µg/mL. Each 
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gp120 type was passed over its dedicated flow channel (Figure 2.2) at a flow-
rate of 25 µL/minute for a duration of six minutes, until immobilisation (amine 
coupling) levels had reach a minimum of 2000 response units (RU). To remove 
gp120 molecules which were uncoupled to the sensor surface or gp120 dimers 
that had formed on the surface, 10 mM glycine at pH 3.5 was passed over 
every flow cell of immobilised gp120 at a flow rate of 100 µL/minute for a 
period of 18 seconds. The flow-channels were then washed with hepes 
buffered saline (HBS; Appendix 2.11) at a flow-rate of 25 µL/minutes for four 
minutes and a new baseline was reached. Excess carboxyl groups were then 
capped using ethanolamine. 
 
For each gp120, six flow cells were available for reactions with the following 6 
analytes (Figure 2.2): kCD4-IgG2wt supernatant (section 2.6.4), kCD4-IgG2S60C 
supernatant (section 2.6.4), negative control supernatant (section 2.6.4), NIH PRO 
542, 2dsCD4wt and 2dsCD4S60C. The purified analytes NIH PRO 542, 2dsCD4wt 
and 2dsCD4S60C were dissolved in HBS to a final concentration of 500 nM. The 
kCD4-IgG2wt culture supernatants contained approximately 5-10 µg 
recombinant protein, whereas the kCD4-IgG2S60C culture supernatant 
contained approximately 25 ng (estimated by Western blot analyses and 
densitometry). All the analytes were passed over each of the six immobilised 
gp120 types individually at a flow-rate of 25 µL/minute for six minutes. The 
reaction surfaces were then washed again with HBS, to remove non-specific 
binding or unbound material from immobilised gp120 at a flow-rate of 25 
µL/minute for a period of 15 minutes and dissociation of the analytes was 
monitored.  
 
To further confirm the specificity of gp120 binding to CD4 containing molecules, the 
monoclonal antibody 17b was passed over the gp120 cells to detect whether CD4 
induced epitopes (CD4i) were exposed. The monoclonal antibody 17b was diluted 
in HBS to a concentration of 500 nM and passed over all reaction surfaces at a 
flow-rate of 25 µL/minutes for four minutes. Unbound or non-specifically bound 
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17b was removed by washing HBS over the reaction surfaces at a flow-rate of 
25 µL/minute for four minutes and the dissociation of 17b was monitored.  
In order to repeat the injection of analytes, 10 mM glycine at pH 2.5 was 
passed over all flow-channels at a flow-rate of 100 µL/minute for a period of 18 
seconds to regenerate the gp120 ligand binding sites. The initial injection of 
analytes to ligands was repeated at a flow-rate of 25 µL/minute for five minutes 
to confirm specificity of the CD4 containing proteins for gp120 (data not 
shown). Data for the SPR studies was analysed using the ProteOn Manager 
Software (Bio-Rad; Hercules, USA) and Microsoft Excel 2007 was used for 
fitting SPR data. The signals obtained from the interspots and control expression 
culture supernatant was subtracted from signals of other analyte-ligand reactions. All 
sensorgrams showing an RU level greater than 3 fold that of the reference sample 
suggested the occurrence of specific binding. 
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Figure 2.2: The GLC sensor chip used for SPR experiments. The blue 
squares represent the 36 interaction spots and the yellow ovals represent the 
84 interspot references. The orange arrows numbered 1 to 6 represent the 
horizontal flow channels in which gp120s CN54, SF162, ZM, ZA, IN and Bal; 
respectively, were immobilised on the chip. The pink arrows numbered 1 to 6 
represent the analytes NIH PRO 542, kCD4-IgG2wt containing supernatant, 
kCD4-IgG2S60C containing supernatant, 2dsCD4wt, 2dsCD4S60C and control 
expression supernatant, respectively, injected into the vertical flow channels.   
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Chapter 3: Results 
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3.1 Computer-modelling of the gp120-2dsCD4 interaction 
Molecular modelling of the gp120-2dsCD4 interaction confirmed the presence of a 
CD4 serine 60 molecule within 4.85 Å distance of a gp120 disulphide (C126-C196) 
(Figure 3.1 A). By mutating the CD4 serine 60 residue to a cysteine residue, a thiol 
group was placed in the vicinity of the gp120 (C126-196C) disulphide, allowing a 
redox exchange reaction to occur between the two proteins (Figure 3.1 B) [180, 211]. 
This mutation was used to design two of the four the constructs used in this study.  
 
3.2 Design of kCD4-IgG2wt and kCD4-IgG2S60C encoding constructs and the 
generation of recombinant plasmid stocks 
The amino acid sequence alignment of kCD4-IgG2wt and kCD4-IgG2S60C heavy and 
light chain sequences, respectively, are shown in Figure 3.2.  The kCD4-IgG2wt and 
kCD4-IgG2S60C HC cDNA inserts encode proteins composed of 530 amino acids 
(1599 bp), whereas the kCD4-IgG2wt and kCD4-IgG2S60C LC cDNA inserts encode 
proteins composed of 310 amino acids (939 bp).  
Each of the cDNA sequences were separately inserted in a pcDNA 3.1 (+) plasmid 
synthesized by GeneArt (Regensburg, Germany), successfully transformed into 
E.coli DH5α and glycerol stocks were generated. The recombinant plasmids were 
then purified on a large scale (Figure 3.3, lanes 9-12).  
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Figure 3.1: Computer-modelling of the gp120-2dsCD4wt (A) and gp120-
2dsCD4S60C (B) interactions. The structures of CD4 (blue) and gp120 (red) are 
displayed in ribbon configuration. The atomic structures of the CD4 serine 60, the 
mutant CD4 cysteine 60, gp120 cysteine 126 and 196 residues are shown in stick 
configuration (yellow represents sulphur atoms, red represents oxygen atoms, blue 
represents a nitrogen atom and white represents carbon atoms). The image was 
viewed with Swiss PDB viewer (version 3.7) [106, 211]. 
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A 
                                                                                                    
                      *        20         *        40         *        60         *        80       
kCD4-IgG2 wt:  MNRGVPFRHLLLVLQLALLPAATQGKKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRA :  80 
kCD4-IgG2 S60c:  ................................................................................ :  80 
                                                                                                    
                      *       100         *       120         *       140         *       160       
kCD4-IgG2 wt:  DSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRG : 160 
kCD4-IgG2 S60c:  .C.............................................................................. : 160 
                                                                                                    
                      *       180         *       200         *       220         *       240       
kCD4-IgG2 wt:  KNIQGGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAFASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP : 240 
kCD4-IgG2 S60c:  ................................................................................ : 240 
                                                                                                    
                      *       260         *       280         *       300         *       320       
kCD4-IgG2 wt:  VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAG : 320 
kCD4-IgG2 S60c:  ................................................................................ : 320 
                                                                                                     
                      *       340         *       360         *       380         *       400       
kCD4-IgG2 wt:  PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGK : 400 
kCD4-IgG2 S60c:  ................................................................................ : 400 
                                                                                                   
                      *       420         *       440         *       460         *       480       
kCD4-IgG2 wt:  EYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPM : 480 
kCD4-IgG2 S60c:  ................................................................................ : 480 
                                                                      
                      *       500         *       520         *       
kCD4-IgG2 wt:  LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK : 530 
kCD4-IgG2 S60c:  .................................................. : 530 
 
 
B                                                                  
                                                                                                    
                      *        20         *        40         *        60         *        80       
kCD4-IgG2 wt:  MNRGVPFRHLLLVLQLALLPAATQGKKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRA :  80 
kCD4-IgG2 S60c:  ................................................................................ :  80 
                                                                                                    
                      *       100         *       120         *       140         *       160       
kCD4-IgG2 wt:  DSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRG : 160 
kCD4-IgG2 S60c:  .C.............................................................................. : 160 
                                                                                                    
                      *       180         *       200         *       220         *       240       
kCD4-IgG2 wt:  KNIQGGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAFTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREA : 240 
kCD4-IgG2 S60c:  ................................................................................ : 240 
                                                                                                     
                     *       260         *       280         *       300         *       
kCD4-IgG2 wt:  KVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC : 310 
kCD4-IgG2 S60c:  ...................................................................... : 310 
                                                                                          
Figure 3.2: Amino acid sequence alignments of the kCD4-IgG2wt and kCD4-
IgG2S60C heavy (A) and light chains (B). Dots indicate identity to the top sequence. 
The amino acids not highlighted represent the CD4 portions of the proteins, amino 
66 
 
acids highlighted blue represent the IgG2 portions of the proteins and the S60C 
mutation is highlighted in yellow. 
 
3.3 Analysis of purified and digested pcDNA 3.1 (+) recombinant constructs 
Single restriction enzyme digest analyses of the pKHwt, pKHS60C, pKLwt and pKLS60C 
constructs loaded in a 0.7% agarose gel are shown in Figure 3.3.  
After digestion with Eco R1, pKHwt and pKHS60C constructs showed the expected 
size of approximately 7100 bp (actual size of 7027 bp) (Figure 3.3, lane 2 and 4 
respectively). The digested pKLwt and pKLS60C constructs display a size of 
approximately 6500 bp (actual size of 6367 bp) (Figure 3.3, lane 6 and 8 
respectively). 
The purified recombinant plasmids were used in all subsequent transient transfection 
experiments.     
 
3.4 Single-transfections for optimal transient expression of each construct in 
HEK293T cells 
Different transfection reagents, recombinant plasmid concentrations and post-
transfection harvest times were successfully compared to establish optimal transient 
expression protocols for each of the four constructs in HEK293T cells.   
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Figure 3.3: Agarose gel electrophoresis analyses of EcoRI digested and 
undigested pKHwt, pKHS60C, pKLwt and pKLS60C constructs after 
purification. Lane 1: Molecular weight marker, lane 2: digested pKHwt, lane 4: 
digested pKHS60C, lane 6: digested pKLwt, lane 8: digested pKLS60C, lane 9: 
undigested pKHwt, lane 10: undigested pKHS60C, lane 11: undigested pKLwt and 
lane 12: undigested pKLS60C. Molecular weights are shown in kilobase pairs 
(kbp) on the left.   
 
3.4.1 Optimized expression of kCD4-IgG2wt LC in HEK293T cells using 
different DNA carriers 
A comparison of the transient expression profiles of pKLwt using the maximum 
amounts of plasmid DNA concentrations recommended for Polyfect transfection 
reagent (4 µg) and Lipofectamine™ (10 µg) in HEK293T cells is shown in Figure 3.4.  
Overall, proteins were transiently expressed in 25 cm3 dishes with 7 mL of culture 
supernatant, harvested at 48 hours post-transfection, concentrated to 500 µL, and 
used (30 µL) for SDS-PAGE and Western blot analyses. The amount of detected 
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kCD4-IgG2wt LC protein expressed from 4 µg of pKLwt using Polyfect transfection 
reagent was similar to the amount of detected kCD4-IgG2wt LC protein expressed 
from 10 µg of pKLwt using Lipofectamine™, thus Polyfect transfection reagent was 
used in all subsequent HEK293T transfection experiments due to the lower plasmid 
concentrations required for transfections and lower cost of reagent. 
Protein expression levels at 24 hours post-transfection were much lower than at 48 
hours post-transfection (results not shown). Supernatants and cells were harvested 
at 48 hours post-transfection in all subsequent single-transfection optimization 
experiments.                           
 
 
Figure 3.4: Western blot image showing the protein expression levels of 4 µg 
and 10 µg of kCD4-IgG2wt LC using Polyfect transfection reagent and 
Lipofectamine™, respectively. Lane 1:  0.5 µg of positive control 4dsCD4S60C, lane 
2: kCD4-IgG2wt LC expression from 10 µg of pKLwt using Lipofectamine™, lane 3: 
kCD4-IgG2wt LC expressed from 4 µg of pKLwt using Polyfect transfection reagent, 
lane 6: negative control culture supernatant. Molecular weights in kilodaltons (kDa) 
are shown on the left. 
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3.4.2 Optimization of protein expression by varying concentrations of 
pKHwt, pKHS60C, pKLwt and pKLS60C with Polyfect transfection reagent 
Levels of proteins expressed in HEK293T cells by transient transfection with 2 µg 
and 4 µg of pKHwt, pKHS60C, pKLwt and pKLS60C with appropriate amounts of Polyfect 
are shown in Figure 3.5.  
The proteins were each expressed in 25 cm3 flasks, 7 mL of culture supernatant, 
concentrated to 500 µL, and 30 µL thereof was analysed by SDS-PAGE and 
Western blot techniques. In addition, the transfected HEK293T cells were lysed with 
500 µL of lysis buffer and 30 µL of the cell-lysate was analysed by SDS-PAGE and 
Western blot (results not shown).  
The kCD4-IgG2wt and kCD4-IgG2S60C LC proteins were secreted into the culture 
supernatant, and similar expression levels of kCD4-IgG2S60C LC protein were seen 
after transient transfections with 2 µg or 4 µg of pKLS60C (Figure 3.5, lanes 6  and 8, 
respectively). The amount of kCD4-IgG2wt LC protein expressed from 4 µg of pKLwt 
was higher than the amount of protein expressed by 4 µg of pKLS60C. 
No expression of the kCD4-IgG2wt or kCD4-IgG2S60C HC proteins in the culture 
supernatant was detected at the two concentrations of pKHwt or pKHS60C tested. 
Interestingly, the kCD4-IgG2wt and kCD4-IgG2S60C HC and LC proteins were all 
detected in the cell-lysate in small quantities (data not shown). 
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Figure 3.5: Western blot image showing the protein expression levels of 2 µg 
and 4 µg of pKLwt, pKLS60C, pKHwt and pKHS60C transfected with Polyfect 
transfection reagent into HEK293T cells in 25 cm3 flasks. Lane 2: kCD4-IgG2wt 
LC expression from 4 µg of pKLwt, lane 3: kCD4-IgG2wt HC expression from 2 µg of 
pKHwt, lane 4: supernatant from untransfected cells, lane 5: kCD4-IgG2wt HC 
expression from 4 µg of pKHwt, lane 6: kCD4-IgG2S60C LC expression from 2 µg of 
pKLS60C, lane 7: kCD4-IgG2S60C HC expression from 2 µg of pKHS60C, lane 8: kCD4-
IgG2S60C LC expressed from 4 µg of pKLS60C, lane 9: kCD4-IgG2S60C HC expressed 
from 4 µg of pKHS60C and lane 10: 0.5 µg of positive control NIH PRO 542. 
 
Overall, transient transfection of HEK293T cells in 25cm3 flasks, using 4 µg 
recombinant plasmid and 40 µL Polyfect transfection reagent, 7 mL culture 
supernatant and proteins being harvested at 48 hours post-transfection were 
considered optimal conditions.  
 
3.5 Co-transfections for transient expression of kCD4-IgG2wt and kCD4-
IgG2S60C heterotetrameric proteins 
The ability of HEK293T cells to produce fully assembled kCD4-IgG2wt and kCD4-
IgG2S60C protein is shown in Figures 3.6 and 3.7, respectively. A total of 400 mL of 
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culture supernatant containing heterotetrameric kCD4-IgG2wt (or kCD4-IgG2S60C) 
was concentrated to 500 µL (or 300 µL), and 60 µL was analysed by SDS-PAGE and 
Western blot analyses under non-reducing (Figure 3.6 A and 3.7) and reducing 
conditions (Figures 3.6 B). 
Co-transfection of HEK293T cells with pKHwt and pKLwt allowed for the expression of 
a heterotetrameric kCD4-IgG2wt molecule of the expected 200 kDa size under 
non-reducing conditions (Figure 3.6 A, lane 6), with individual heavy chains (65 
kDa) and light chains (35 kDa) seen under reducing conditions (Figure 3.6B, 
lane 6). CD4 containing proteins of 130 kDa size were observed and presumed 
to be HC homodimers of kCD4-IgG2wt (Figure 3.6 A, lane 6). The amount of 
assembled kCD4-IgG2wt protein in the sample is approximately 0.6 µg, as 
determined by densitometry analysis (Figure 3.6 A, lane 6).  Molecules smaller 
than 35 kDa size were excluded after the concentration step. The decreasing 
concentrations of the NIH PRO 542 positive control were used to quantify the 
amount of heterotetrameric kCD4-IgG2wt present in the samples to greater 
than 500 ng. The heavy chains of NIH PRO 542 were not observed under 
reducing conditions, however. The amounts of detectable heavy chains of PRO 
542 may be greater than 500 ng for this Western blotting analysis. 
Under non-reducing conditions, supernatant analysis of co-transfections of HEK293T 
cells with pKHS60C and pKLS60C did not show high levels of the expected 200 kDa 
sized heterotetrameric kCD4-IgG2S60C molecule, but the individual heavy and 
light chains are visible in relatively high amounts (Figure 3.7, lane 1). 
Considering that molecules smaller than 35 kDa were excluded during the 
concentration step, the 35 kDa size kCD4-IgG2S60C LC proteins were not 
expected to be detected. Heterotetrameric kCD4-IgG2S60C protein is likely to be 
more unstable than the heterotetrameric kCD4-IgG2wt protein as more 
unassembled product is observed for the former compared to the latter. According 
to the NIH PRO 542 standard, the amount of heterotetrameric kCD4-IgG2S60C 
expressed was considerably lower than 500 ng (approximately 25 ng) as 
determined by Western blot and densitometry analysis. 
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Figure 3.6: Western blot image showing expressed amounts of kCD4-
IgG2wt, NIH PRO 542 standards and control expression culture 
supernatant, under non-reducing (A) and reducing conditions (B). Lane 1: 
500 ng of NIH PRO 542, lane 2: 250 ng of NIH PRO 542, lane 3: 100 ng of NIH 
PRO 542, lane 4: 50 ng of NIH PRO 542, lane 5: concentrated negative control 
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culture supernatant and lane 6: concentrated kCD4-IgG2wt containing culture 
supernatant. The arrow indicates kCD4-IgG2wt HC expressed. 
 
 
Figure 3.7: Western blot image showing expressed amounts of kCD4-
IgG2S60C with an NIH PRO 542 standard and control expression culture 
supernatant under non-reducing conditions. Lane 1: concentrated kCD4-
IgG2S60C containing culture supernatant, lane 2: concentrated negative control 
culture supernatant and lane 3: 500 ng of NIH PRO 542.  
 
Overall, transient transfections were repeated under the optimal conditions described 
above, where culture supernatant containing heterotetrameric proteins was 
harvested, concentrated (where required), and used to establish purification 
protocols.  
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3.6 Purification of heterotetrameric kCD4-IgG2wt and heterotetrameric kCD4-
IgG2S60C  
Several protocols for the purification of heterotetrameric kCD4-IgG2wt and kCD4-
IgG2S60C were evaluated using Protein-A resin from a column and beads. Expression 
of the relevant constructs was confirmed by SDS-PAGE and Western blot analysis 
prior to using the supernatant for purification.   
 
3.6.1 Purification of heterotetrameric kCD4-IgG2wt from serum-free 
conditioned medium using the Äkta FPLC system 
Attempts to purify kCD4-IgG2wt from culture supernatant loaded onto a Protein-A 
column was of limited success (results not shown). Overall, while monitoring the 
absorbance (A280) of the sample during the purification process, a negligible amount 
(< 100 milliamps units) of protein was detected in the wash step, elution step and 
regeneration step. SDS-PAGE and Western blot analysis of concentrated flow-
through, washes, eluate, regeneration solutions, and Protein-A resin from the column 
confirmed the absence of heterotetrameric kCD4-IgG2wt. 
Based on the volumes used, low concentrations of proteins expressed, and low 
binding capacity of the Protein-A resin used above, further purification protocols 
using Protein-A agarose beads from manufacturers other than GE Healthcare were 
investigated. 
 
3.6.2 Purification of heterotetrameric kCD4-IgG2wt and heterotetrameric 
kCD4-IgG2S60C using Protein-A agarose beads                 
An affinity purification protocol of heterotetrameric kCD4-IgG2wt and kCD4-
IgG2S60C using Protein-A agarose beads purchased from Bio-Rad (Hercules, 
USA) confirmed that the recombinant proteins could bind to the beads, but 
could not be effectively eluted.  
Volumes of 65-70 mL of heterotetrameric kCD-IgG2wt containing culture 
supernatant were routinely incubated with 1 mL of Protein-A agarose beads, 
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and 35 mL of kCD4-IgG2S60C containing culture supernatant was then 
incubated with 0.5 mL of Protein-A agarose beads. Subsequently, 30 µL of the 
initial unbound material, bound material adsorbed to beads, concentrated washes, 
concentrated eluate and concentrated regenerate were analysed by SDS-PAGE and 
Western blot techniques (Figure 3.8). The kCD4-IgG2wt heterotetramer was 
expressed (Figure 3.8 A, lane 9) and observed to bind Protein-A agarose beads 
(Figure 3.8 A, lane 10). Inability to detect kCD4-IgG2wt in the eluate suggested 
that the recombinant proteins could not effectively dissociate from the beads.  It 
was likely that small amounts of undetected kCD4-IgG2wt were eluted, but 
were undetectable.   
 
Similar results were seen of the kCD4-IgG2S60C protein binding to the Protein-A 
beads, but with much lower amounts of proteins detected on the beads (Figure 3.8 
B, lane 1).  
To confirm that the kCD4-IgG2wt and kCD4-IgG2S60C proteins were still bound 
to the beads, a different elution buffer (0.1 M sodium acetate buffer at pH 3.5) 
was employed to elute the proteins. Elution of detectable amounts of kCD4-
IgG2wt and kCD4-IgG2S60C with the sodium acetate buffer proved unsuccessful 
as well (data not shown).     
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Figure 3.8 A: Western blot image showing samples of the steps during the 
purification process of kCD4-IgG2wt. Lane 2: 1 µg of NIH PRO 542, lane 5: 
regenerate, lane 6: eluate, lane 7: washes, lane 9: concentrated supernatant 
sample before purification and lane 10: 30 µL of Protein-A beads with 
adsorbed heterotetrameric kCD4-IgG2wt after 72 hours incubation of beads 
with kCD4-IgG2wt containing culture supernatant. The arrow indicates kCD4-
IgG2wt bound to beads. 
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Figure 3.8 B: Western blot image showing the analysis of the samples 
collected during the purification of kCD4-IgG2S60C. Lane 1: 30 µL of 
Protein-A beads with adsorbed heterotetrameric kCD4-IgG2S60C after 72 hour 
incubation of beads with kCD4-IgG2S60C containing culture supernatant, Lane 
2: concentrated supernatant before purification, lane 3: washes, lane 4: eluate, 
lane 5: regenerate, lane 10: 1 µg of NIH PRO 542. The arrow indicates kCD4-
IgG2S60C bound to beads. 
 
3.7 Immunoprecipitation of HIV gp120 by heterotetrameric kCD4-IgG2wt bound 
to Protein-A agarose beads 
3.7.1 Optimal binding of kCD4-IgG2wt to Protein-A agarose beads   
In preparation of the immunoprecipitation of gp120 using NIH PRO 542 and kCD4-
IgG2wt (both adsorbed to Protein-A agarose beads), the binding capacity of the 
Protein-A beads was measured.  Concurrently, the ability of gp120 Bal and 93TH975 
to bind to the anti-gp120 antibody cocktail (composed of Chessie 13-39.1 
supernatant, ID6 and NEA-9301) was assessed.    
Figure 3.9 A shows that equivalent amounts of kCD4-IgG2wt and NIH PRO542 
positive control bind to the same amount of Protein-A agarose beads.  Also detected 
binding to the Protein-A agarose beads were the HC homodimers of PRO 542 and 
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kCD4-IgG2wt (130 kDa size) (Fig 3.9 A lanes 3 and 5, respectively) which migrated 
similar distances as gp120 Bal (Fig 3.9 B, lane 8).  
Interestingly, the anti-gp120 antibody cocktail detected gp120 Bal, but not gp120 
93TH975 (Figure 3.9 B).  
Immunoprecipitation assays were conducted using gp120 Bal, with the same 
amounts of PRO 542 (as a control) and kCD4-IgG2wt. 
 
3.7.2 Immunoprecipitation of HIV gp120 by heterotetrameric kCD4-IgG2wt 
bound to Protein-A agarose beads 
The gp120 Bal protein bound to heterotetrameric NIH PRO 542 and kCD4-IgG2wt 
(pre-incubated with Protein-A agarose beads) implying that the CD4 containing 
proteins were fully folded and had functional CD4 and Fc portions (Figure 3.10, lanes 
3 and 7, respectively). Based on the ability of fully folded kCD4-IgG2wt and kCD4-
IgG2S60C to bind Protein-A agarose beads and the ability of heterotetrameric kCD4-
IgG2wt to bind gp120 Bal, surface plasmon resonance (SPR) experiments were 
conducted to confirm the specificity of kCD4-IgG2wt and kCD4-IgG2S60C for various 
gp120s.    
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Figure 3.9: Western blot image showing the binding capacity of Protein-A 
agarose beads to kCD4-IgG2wt using anti-CD4 antibodies (A) and detection of 
gp120 using anti-gp120 antibodies (B). Lane 1: Protein-A beads incubated with 
negative control expression culture supernatant, lane 2: Unbound materials to 
Protein-A beads from control expression culture supernatant, lane 3: Protein-A 
beads incubated with NIH PRO 542, lane 4: Unbound NIH PRO 542 to Protein-A 
beads, lane 5: kCD4-IgG2wt containing culture supernatant incubated with Protein-A 
beads, lane 6: Unbound kCD4-IgG2wt to Protein-A beads, lane 7: 0.5 µg of HIV 
gp120 93TH975, lane 8: 0.5 µg of HIV gp120 Bal and lane 9: 1 µg of NIH PRO 542.  
80 
 
 
 
Figure 3.10: Western blot image of the immunoprecipitation of HIV-1 gp120 Bal 
by kCD4-IgG2wt adsorbed to Protein-A agarose beads. Lane 1: Protein-A beads 
incubated with control culture supernatant only, lane 2: gp120 Bal bound to Protein-A 
beads treated with control culture supernatant, lane 3: gp120 Bal bound to Protein-A 
beads with adsorbed NIH PRO 542, lane 4: unbound gp120 from Protein-A beads 
with adsorbed NIH PRO 542, lane 5: Protein-A beads only, lane 6: unbound gp120 
to Protein-A beads, lane 7: gp120 Bal bound to Protein-A beads with adsorbed 
kCD4-IgG2wt, lane 8: unbound  gp120 from Protein-A beads with adsorbed kCD4-
IgG2wt. 
 
3.8 SPR analysis of gp120 binding to heterotetrameric kCD4-IgG2wt and 
heterotetrameric kCD4-IgG2S60C 
The ability of kCD4-IgG2wt and kCD4-IgG2S60C (in supernatant) to bind gp120 from 
different HIV-1 subtype B and C isolates, as compared to NIH PRO 542, 2dsCD4wt 
and 2dsCD4S60C, was successfully determined by SPR (Figure 3.11).  
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The sensorgrams (Figure 3.11) show the intensity of interaction of the various 
analytes interacting with different gp120 ligands over time and are measured in 
response units (RU). Figures 3.11 A to 3.11 F show six different analytes binding to 
six gp120s, whereas Figures 3.11 G to 3.11 L show the level of binding of MAb 17b 
to the gp120s CD4i after analyte binding. 
 
Overall, the kCD4-IgG2wt protein in supernatant was capable of binding the panel of 
six gp120s (Figure 3.11 A-F). Only two gp120s did not have their CD4 induced 
epitopes (CD4i) exposed by kCD4-IgG2wt for MAb 17b binding (Figure 3.11 G and 
K). The kCD4-IgG2S60C protein in supernatant was not detected to bind any of the 
gp120s. Surprisingly the CoRbs of four out of six gp120s was minimally exposed for 
MAb 17b binding by kCD4-IgG2S60C (Figure 3.11 G, H, K and L).  
 
PRO 542 from the NIH was observed to bind all gp120s with RU levels greater than 
1000 except for gp120 ZM (RU of approximately 620, Figure 3.11 E). All the 
sensorgrams displaying NIH PRO 542 binding to gp120 showed an association 
phase, equilibrium and dissociation phase. Although NIH PRO 542 was able to bind 
all the gp120s, it was unable to elicit the CD4i of gp120 CN54 and ZM (Figure 3.11 G 
and K) for MAb 17b binding. The gp120s which had their CD4i exposed by NIH PRO 
542 (gp120 SF162, IN, ZA and Bal) could bind minimally to MAb 17b with RU levels 
between 20 and 50 (Figure 3.11 H, I, J and L). 
 
The 2dsCD4wt protein was observed to bind the six gp120s with RU levels greater 
than 600 except for gp120 ZM and Bal (RU levels of 300 and 400, respectively; 
Figure 3.11 E and F). As with NIH PRO 542, an association, equilibrium and 
dissociation phase was observed with all 2dsCD4wt-gp120 interactions. The 
2dsCD4wt protein was capable of exposing the CD4i of five gp120s with RU levels 
ranging from 40 to 135 (Figure 3.11 G, H, I, J, and L).  The sensorgrams showing 
MAb 17b binding gp120s also have distinct association, equilibrium and dissociation 
phases.  
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The 2dsCD4S60C protein was found to bind gp120 CN54, SF162, IN, ZA and Bal 
(Figure 3.11 A to F) in similar amounts to NIH PRO 542. Notably, 2dsCD4S60C 
showed significantly higher binding to gp120 ZM than NIH PRO 542 (Figure 3.11 E). 
The sensorgrams of 2dsCD4S60C interacting with gp120 all have distortions in the 
association phase due to air bubbles that were introduced onto the chip surface, 
because the sample volume was slightly low upon injection, but did not affect the 
subsequent interaction of 2dsCD4S60C with gp120 significantly. All of the 
2dsCD4S60C-gp120 interactions were observed to have association, equilibrium and 
dissociation phases as the NIH PRO 542-gp120 interactions. The 2dsCD4S60C 
protein, as NIH PRO 542, was unable to expose the CD4i of gp120 CN54 and ZM 
(Figure 3.11 G and K). The gp120s which had their CD4i exposed (gp120 SF162, IN, 
ZA and Bal) bound MAb 17b in highly similar levels to those observed when NIH 
PRO 542 elicited the CD4i (Figure 3.11 H, I, J and L).  
The kCD4-IgG2wt protein in supernatant bound all six gp120s with RU levels greater 
than 180 (Figure 3.11 A to F). The interactions with gp120 all involved an 
association, equilibrium and dissociation phase. Interestingly, little amount of 
dissociation from gp120 was observed by kCD4-IgG2wt except in the cases of gp120 
IN and ZA, where a relatively large amount of kCD4-IgG2wt dissociated from the 
gp120s (Figure 3.11, C and D). Notably, the concentration of kCD4-IgG2wt in 
supernatant interacting with the gp120s was approximately half that of NIH PRO 
542, however NIH PRO 542 bound the same gp120s with 5 fold higher RU levels. 
The kCD4-IgG2wt protein was observed to expose the CD4i of gp120 SF162 and ZA 
in similar amounts to NIH PRO 542 and 2dsCD4S60C. Overall, kCD4-IgG2wt could not 
elicit the CD4i of gp120 CN54 and gp120 ZM (Figure 3.11 G and K), but registered 
MAb 17b binding RU levels greater than 20 where elicitation occurred, except in the 
case of gp120 Bal (RU level of approximately 10; Figure 3.11 L). 
The kCD4-IgG2S60C protein in supernatant could not register binding to any gp120; 
however this is attributed to low amounts of the heterotetramer present in the 
supernatant sample (approximately 25 ng). Even though no protein was observed to 
bind gp120 from the kCD4-IgG2S60C supernatant, elicitation of the gp120 CN54, 
SF162, ZM and Bal CD4i were observed (Figure 3.11 G, H, K and L).  
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Figure 3.11: The interactions of selected analytes with various immobilised 
gp120 from HIV clades B and C (A-F), as well as the binding of MAb 17b to the 
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CD4i of various gp120s exposed by the selected analytes (G-L). The 
sensorgrams coloured blue are relevant to NIH PRO 542, green sensorgrams are 
relevant to 2dsCD4S60C, black sensorgrams are relevant to 2dsCD4wt, red 
sensorgrams are relevant to kCD4-IgG2S60C in supernatant, purple sensorgrams are 
relevant to kCD4-IgG2wt in supernatant and yellow sensorgrams are relevant to the 
control supernatant.  
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Chapter 4: Discussion 
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The overall aim of this study was to design and produce a novel form of CD4-IgG2 
(kCD4-IgG2wt) which would be structurally and functionally identical to PRO 542, 
composed of CD4 domains one and two (D1D2) replacing the variable heavy and 
light chain regions of IgG2. A mutant version of the CD4-IgG2 protein (kCD4-
IgG2S60C) was also generated, which had an S60C mutation in the CD4 portions, 
intended to increase the affinity of kCD4-IgG2wt for HIV-1 gp120. Overall, the 
structural integrity of heterotetrameric kCD4-IgG2wt and kCD4-IgG2S60C proteins was 
determined by incubating the proteins with an anti-CD4 antibody (MT310) and or the 
binding of the proteins to Protein-A agarose beads. For comparison, PRO 542 
(donated by the NIH) was used as a positive control. Protein-A affinity 
chromatography protocols were then employed to purify kCD4-IgG2wt and kCD4-
IgG2S60C, albeit with limited success. Ultimately, the functional specificity of kCD4-
IgG2wt and kCD4-IgG2S60C was evaluated using SPR. The kCD4-IgG2wt and kCD4-
IgG2S60C proteins abilities to bind various gp120 molecules from HIV clades B and C 
were tested; using NIH PRO 542, 2dsCD4wt and 2dsCD4S60C as positive controls. 
Following is a discussion of the results obtained. 
 
4.1 The design and synthesis of the kCD4-IgG2wt and kCD4-IgG2S60C encoding 
expression vectors 
HIV (which causes AIDS) binds to cell-surface CD4 protein expressed on CD4+ T 
cells, monocytes and macrophages using the viral gp120 envelope glycoprotein 
receptor as the initial step in the infection process [22, 213, 214]. In light of this, 
therapeutic molecules that incorporate the gp120 binding site of CD4 neutralise HIV 
potently [153, 164, 165, 167-169, 174, 176, 177, 181, 190, 191, 194, 195, 215-218]. 
Soluble CD4 and CD4-immunoglobulin fusions have been formulated to mimic cell-
surface CD4 structurally and functionally [164, 169-171, 174, 175, 179, 183, 185, 
190, 191, 217, 219]. The CD4-based agents are capable of uncoating HIV of its 
gp120 protein, competitively inhibiting HIV binding to cell-surface CD4 and reducing 
cell-to cell spread of HIV by syncytium formation [169, 177, 179, 220]. 
One polyvalent CD4-based agent showing great activity against HIV is PRO 542, 
produced by Progenics Pharmaceuticals, Inc of Tarrytown, New York. PRO 542 is a 
heterotetrameric protein comprised of the CD4 D1D2 regions fused to the CH1 
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region of IgG2 and the constant domain of human kappa light chains. By virtue of 
incorporating an IgG2 Fc portion in the design of PRO 542, the heterotetramer 
displays increased serum life-time compared to soluble CD4. In addition, PRO 542 
has higher avidity for HIV than the monovalent soluble CD4 or divalent CD4-Ig [153, 
220-222]. 
In this study, the unique design and production of a PRO 542-like molecule is 
described. In addition, a mutant form of PRO 542 was uniquely generated in this 
study, to bind gp120 with higher affinity. The mutant forms of PRO 542 have not 
been characterised. 
To produce PRO 542, Beaudry et al (1992) designed and synthesised the CD4-
IgG2HC-pRcCMV (ATCC no. 75193) and CD4-kLC-pRcCMV (ATCC no. 75194) 
expression vectors which encode the heavy chains (HC) and light chains (LC) of 
PRO 542, respectively. The sequence encoding the LC of PRO 542 was 
subsequently sub-cloned from CD4-kLC-pRcCMV into pPPI-2, which contains the β-
globin promoter that directs the transcription of the dihydrofolate reductase gene 
(DHFR). The sequence encoding the HC of PRO 542 was constructed using 
genomic DNA (containing introns) whereas the light chain encoding sequence did 
not contain introns. Both the HC and LC encoding sequences of PRO 542 were 
inserted in separate expression vectors, containing, among other elements, the 
Human cytomegalovirus immediate-early (CMV) promoter [153, 206, 207, 220]. 
 In contrast, the sequence used to encode the HC of kCD4-IgG2wt in this study was 
exclusively cDNA in nature. The cDNA sequence encoding D1D2 domains of CD4 
was fused to the first codon encoding the CH1 region of an IgG2 Fc portion. The 
kCD4-IgG2wt HC encoding sequence was then synthesized and inserted in a pcDNA 
3.1 (+) plasmid by GeneArt (Regensburg, Germany) and the whole construct was 
called pKHwt. 
The LC encoding sequence of kCD4-IgG2wt, however, was designed identically to 
the sequences encoding the LC of PRO 542 described by Beaudry et al (1992) 
[220]. The cDNA sequence encoding the D1D2 region of CD4 was fused to the first 
codon encoding the human constant kappa light chain portion. The complete kCD4-
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IgG2wt LC encoding sequence was synthesized and inserted in a pcDNA 3.1 (+) 
plasmid by GeneArt, and the whole construct was referred to as pKLwt. 
The HC and LC encoding cDNA sequences of kCD4-IgG2S60C were identical to the 
HC and LC cDNA sequences of kCD4-IgG2wt, respectively, except at the codons 
coding for residue 60 in the CD4 portions. The HC and LC cDNA sequences of 
kCD4-IgG2S60C contain a codon coding for a cysteine residue at position 60 in the 
CD4 portions. The HC and LC cDNA sequences of kCD4-IgG2wt, however, contain a 
codon coding for a serine 60 residue in the CD4 portions. The kCD4-IgG2S60C LC 
encoding cDNA sequence was synthesized and inserted in a pcDNA 3.1 (+) plasmid 
by GeneArt and the whole construct was referred to as pKLS60C. In addition, the 
kCD4-IgG2S60C HC encoding cDNA sequence was also inserted in a separate 
pcDNA 3.1 (+) plasmid and referred to as pKHS60C. The pKHS60C construct was also 
synthesized by GeneArt. 
To express the individual chains of the kCD4-IgGwt and kCD4-IgG2S60C, the pcDNA 
3.1 (+) expression vector was selected as it contains the Human cytomegalovirus 
immediate-early (CMV) promoter (as constructs used to express PRO 542 HC and 
LC) which permits high protein expression levels in a wide variety of mammalian 
cells [153, 220, 222]. In addition, the cDNA sequences coding for the individual 
chains of kCD4-IgG2wt and kCD4-IgG2S60C were codon-optimized for expression in 
mammalian cells.  
 
4.2 Single-expression studies of pKHwt, pKHS60C, pKLwt and pKLS60C 
Two and four micrograms of pKHwt, pKHS60C, pKLwt and pKLS60C constructs were 
transfected into HEK293T cells in 25 cm3 flasks using Polyfect transfect transfection 
reagent. After 48 hours, the recombinant protein expression levels of the individual 
constructs were measured.  
The secretion of kCD4-IgG2wt and kCD4-IgG2S60C HC protein was not observed in 
the culture supernatant after 2 or 4 µg of pKHwt and pKHS60C was transfected into 
HEK293T cells. This observation was unsurprising as previous studies have shown 
that individual HC or HC homodimers are not secreted into the supernatant, but are 
retained intracellularly [223]. Newly synthesized HC proteins are not secreted, but 
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are bound to heavy chain binding protein (BiP) in the endoplasmic reticulum until 
they are matched with LC proteins [224, 225]. Analysis of the cell-lysates from cells 
producing kCD4-IgG2wt and kCD4-IgG2S60C HC revealed the presence of HC protein 
(65 kDa in size), however we did not quantify the amounts of intracellularly retained 
HC.  
Four micrograms of the pKLwt construct was able to express kCD4-IgG2wt LC protein 
with a size of 35 kDa, observed in Western blot analysis (Figure 3.5). Expectedly, 
HEK293T cells were capable of producing and secreting LC protein into the culture 
supernatant. In contrast, 2 and 4 µg of pKLS60C construct transfected into HEK293T 
cells both produced approximately one fifth the amount of LC protein that pKLwt 
produced (Figure 3.5), according to Western blot and densitometry analysis. It is 
unclear why the amounts of secreted kCD4-IgG2S60C LC were lower compared to 
secreted kCD4-IgG2wt; however the S60C mutation may have reduced the amount of 
secreted protein or the stability of the protein. It is suspected that the S60C mutation 
may have delayed the maturation of fully folded LC proteins, causing the protein to 
be retained intracellularly.  
 
4.3 Co-transfection of pKHwt with pKLwt to produce heterotetrameric kCD4-
IgG2wt, as well as the co-transfection of pKHS60C with pKLS60C for the 
production of heterotetrameric kCD4-IgG2S60C 
To confirm the ability of HEK293T cells to produce heterotetrameric kCD4-IgG2wt 
protein identical to PRO 542, described by Beaudry et al (1992), the pKHwt and pKLwt 
were co-transfected in HEK293T cells. Concurrently, the pKHS60C and pKLS60C 
constructs were also co-transfected to evaluate the ability of HEK293T cells to 
produce heterotetrameric KCD4-IgG2S60C.  
The co-transfection of pKHwt with pKLwt in HEK293T cells allowed for the production 
of individual kCD4-IgG2wt HC and LC proteins, which assembled together to form 
heterotetrameric kCD4-IgG2wt protein (200 kDa in size) that was secreted into the 
culture supernatant (Figure 3.6 A, lane 6). According to the NIH PRO 542 standards 
used in the Western blot analysis and densitometry, approximately 0.6 µg of 
heterotetrameric kCD4-IgG2wt protein was present in the analysed sample obtained 
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from the culture supernatant containing heterotetrameric kCD4-IgG2wt protein. 
Overall, this implied that a total of approximately 10 µg of heterotetrameric kCD4-
IgG2wt protein was expressed in 400 mL of culture supernatant. 
Co-transfection of pKHS60C with pKLS60C in HEK293T cells permitted the expression 
of individual kCD4-IgG2S60C HC and LC proteins which assembled together to 
produce a heterotetramer (of 200 kDa size) which was secreted into the culture 
supernatant (Figure 3.7, lane 1) as well. The amounts of heterotetrameric kCD4-
IgG2S60C secreted were exceedingly low compared to amounts of secreted 
heterotetrameric kCD4-IgG2wt. In fact, it is estimated that approximately 25 ng of 
heterotetrameric kCD4-IgG2S60C was observed in the sample analysed using 
Western blot and densitometry. Also observed in the same sample, were relatively 
large amounts of HC and LC of kCD4-IgG2S60C (65 kDa and 35 kDa in size, 
respectively) compared to amounts of heterotetramer. Considering that proteins 
having a size less than 50 kDa were excluded from the sample after the 
concentrating process, no uncoupled LC proteins were expected to be seen in the 
sample. Also, no uncoupled HC proteins are secreted [224, 225], suggesting that 
large amounts of heterotetrameric kCD4-IgG2S60C were unstable and had 
disassembled into component protein chains after secretion. In total, it estimated that 
0.4 µg of assembled heterotetrameric kCD4-IgG2S60C were produced in 400 mL of 
culture supernatant. This result highlights the fact that the S60C mutation affects the 
assembly and secretion of heterotetrameric kCD4-IgG2S60C adversely. To improve 
the yield of stable heterotetramers, alternative strategies ought to be investigated. 
A variety of methods to produce PRO 542 are described, which may be employed to 
improve the yield of heterotetrameric kCD4-IgG2wt and kCD4-IgG2S60C [153, 220, 
222]. Beaudry et al (1992) produced PRO 542 by transiently co-transfecting 
equimolar amounts of CsCl-purified CD4-IgG2HC-pRcCMV and CD4-kLC-pPPI-2 
expression vectors, in African green monkey kidney (CosM5) cells using the calcium-
phosphate precipitation technique [220, 222]. Thereafter, Beaudry et al (1995) 
produced PRO 542 by stably expressing the heterotetramer in DXB-11 Chinese 
hamster ovary (CHO) cells deficient of DHFR. This was achieved by transfecting 20 
µg of CD4-IgG2HC-pRcCMV, 20 µg of CD4-kLC-pPPI-2 and 20 ng of p410 
(encoding DHRF) into the DXB-11 CHO cells and selecting for transfectants 
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producing PRO 542 using step-wise increases of methotrexate. The amounts of 
PRO 542 generated by transient and stable expression are not documented however 
[153, 220, 222]. By employing some of these strategies, the yield of kCD4-IgG2wt 
and kCD4-IgG2S60C may be improved.  
In order to increase the yield of fully folded and assembled heterotetrameric kCD4-
IgG2wt or kCD4-IgG2S60C, one may attempt producing them in bacterial systems. 
One may effectively use Escherichia coli (E. coli) BL21(DE3) or HB2151 cells, which 
are deficient in cellular proteases, to produce the heterotetrameric IgG and extract 
the protein from the bacterial periplasmic space [226]. Alternatively, the individual 
chains of the heterotetramers may be produced separately in bacterial cells and 
refolded in vitro [227-230].  
 
4.4 Purification of heterotetrameric kCD4-IgG2wt and heterotetrameric kCD4-
IgG2S60C 
The heterotetrameric kCD4-IgG2wt and kCD4-IgG2S60C proteins were purified using 
Protein-A affinity chromatography with limited success. Both of the heterotetramers 
were observed to bind Protein-A agarose beads, but not a HiTrap Protein-A HP 
column (from GE Healthcare). 
Protein-A is an antigen derived from the cell wall of Staphylococcus Aureaus (S. 
aureus) which reacts with human gamma globulins [231]. Protein-A is a 42 kDa 
protein which has four binding sites specific for the Fc portions of IgG. The 
interaction between Protein-A and the IgG Fc is relatively strong and specific (Ka is 
approximately 1 x 108 M). It is therefore highly effective to use immobilised Protein-A 
for the purpose of precipitating or purifying IgG Fc containing molecules, as the 
interaction occurs readily at physiologic conditions (pH 7 to 7.2). 
To purify kCD4-IgG2wt, supernatant containing kCD4-IgG2wt was loaded in a HiTrap 
Protein-A HP column (from GE Healthcare) (pre-equilibrated with PBS). The 
unbound proteins were washed off the column and the bound proteins were then 
eluted with a sodium acetate buffer at pH 3.5 into aliquots of 1M tris/HCl at pH 9. The 
heterotetrameric kCD4-IgG2wt protein was not detected in the eluate, washes and 
regenerate. It is likely that some kCD4-IgG2wt protein was removed from the column 
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in the wash step, reducing the amount of protein remaining on the column for elution. 
Therefore, the amounts of kCD4-IgG2wt protein which were eluted may have been 
below the detection limits of the Western blot analysis and densitometry. 
 
In comparison, Beaudry et al (1992) and Beaudry et al (1995) passed supernatant 
containing PRO 542 through a Protein-A Sepharose fast flow column (pre-
equilibrated with PBS) at a flow rate of 60 mL/hour. After extensive washing, PRO 
542 was eluted with 100 mM glycine/HCl buffer at pH 3.5, directly into aliquots of 1 M 
tris/HCl at pH 8, to neutralise the fractions. Beaudry et al (1992) purified PRO 542 
successfully in this manner [153, 220, 222]. 
An alternative method of purifying kCD4-IgG2wt and kCD4-IgG2S60C was therefore 
employed, using Protein-A agarose beads from Bio-Rad, in a batch-type process 
instead of the HiTrap Protein-A HP column.  The supernatants containing 
heterotetrameric kCD4-IgG2wt and kCD4-IgG2S60C proteins were incubated with 
Protein-A agarose beads (pre-equilibrated with sodium phosphate buffer pH 6.5-7). 
The beads were then washed thoroughly to remove unbound proteins, before the 
bound proteins were eluted in acidic conditions (citric acid buffer pH 3.5/sodium 
acetate buffer pH 3.5) into aliquots of 1 M tris/HCl at pH 9. Following the elution step, 
the Protein-A beads were regenerated. It was observed that both heterotetrameric 
kCD4-IgG2wt and kCD4-IgG2S60C proteins were capable of binding Protein-A beads, 
but could not be detected in the eluate. No heterotetrameric kCD4-IgG2wt and kCD4-
IgG2S60C proteins were observed in the eluate, wash or regenerate for that matter. 
The washing of the kCD4-IgG2wt and kCD4-IgG2S60C proteins may have reduced the 
amounts of protein remaining on the column for elution. The eluted proteins may 
have been at amounts too low to detect in the Western blot analysis and 
densitometry.  
The amounts of heterotetrameric kCD4-IgG2wt observed to bind the Protein-A 
agarose beads were considerably larger than those of kCD4-IgG2S60C proteins 
bound to beads, however. Due to the exceedingly low expression and secretion of 
kCD4-IgG2S60C; coupled with low precipitation by Protein-A, it became clear that 
interventions to improve expression efficiency of kCD4-IgG2S60C are required. 
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Further functional characterisation of kCD4-IgG2S60C was limited, in view of the low 
amounts of the heterotetramer produced. 
 
4.5 The immunoprecipitation of gp120 by heterotetrameric kCD4-IgG2wt 
adsorbed to Protein-A agarose beads 
The structural integrity of heterotetrameric kCD4-IgG2wt was assessed successfully, 
in spite of the inability to elute the heterotetramer from a Protein-A column and 
beads. Heterotetrameric kCD4-IgG2wt, adsorbed to Protein-A agarose beads, was 
capable of binding gp120 Bal.  
HIV gp120 binds specifically and stably to the D1D2 regions of soluble CD4 
derivatives with similar affinity to cell-surface CD4 (KD of approximately 1 x 10
-9 M) 
[166, 180, 232].  
Fully assembled and folded heterotetrameric kCD4-IgG2wt was expected to bind 
gp120 like NIH PRO 542. The heterotetrameric kCD4-IgG2wt containing supernatant 
and NIH PRO 542 in PBS were incubated with Protein-A agarose beads from Bio-
Rad. It was observed that similar amounts of heterotetrameric kCD4-IgG2wt and NIH 
PRO 542 remained adsorbed to the beads after thorough washing. The gp120 Bal 
protein was then incubated with kCD4-IgG2wt-Protein-A complexes and NIH PRO 
542-Protein-A complexes. It was observed that gp120 Bal binds to kCD4-IgG2wt-
Protein-A complexes in similar amounts to NIH PRO 542-Protein-A complexes. The 
results showed that the heterotetrameric kCD4-IgG2wt protein expressed in this study 
was not only fully folded and assembled, but functional by virtue of binding Protein-A 
and gp120, concurrently, as NIH PRO 542.  
NIH PRO 542 binds to gp120 from genetically diverse strains of HIV-1 [6, 82, 200, 
202, 203, 233]. To confirm that heterotetrameric kCD4-IgG2wt and kCD4-IgG2S60C 
expressed in this study had similar activity against various gp120s as NIH PRO 542, 
SPR studies were conducted.  
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4.6 SPR studies 
SPR is a technique used to measure interactions between unlabelled molecules, in 
real-time and with high sensitivity. Information obtained from SPR is the change in 
mass on a gold-plated sensor surface, induced by an immobilised ligand binding to 
its cognate receptor. The changes in refractive index at the site of the ligand-analyte 
interaction are plotted against time to generate a sensorgram. If no changes in 
refractive index (response units (RU)) are observed over time, it is assumed that the 
ligand and analyte do not bind each other. If the change in refractive index increases 
over time, it is suggestive that ligand and analyte bind to each other. Due to the low 
amounts of ligands and analyte required and the sensitivity of the technique, SPR is 
a popular choice for binding studies [234-242]. 
The gp120-2dsCD4 interaction has been characterised by Zhou et al (2007), as well 
as Cerutti et al. (2010) using SPR [180, 232]. In addition, the interaction of 
2dsCD4S60C (refer to 1.7.4.3) with gp120 was also characterised by Cerutti et al 
(2010). The affinity calculated for the gp120-2dsCD4wt interaction was 53 nM, 
whereas the affinity calculated for the gp120-2dsCD4S60C interaction was 6 nM. Both 
the 2dsCD4wt and 2dsCD4S60C proteins were observed to associate with gp120 in 
similar amounts, however the 2dsCD4S60C protein was found to dissociate from 
gp120  less rapidly than 2dsCD4wt [180].  
In this study, SPR was used to determine the functional specificity of 
heterotetrameric kCD4-IgG2wt and kCD4-IgG2S60C (both in supernatant) (analytes) 
by passing the heterotetramers over six different gp120s (ligands) from HIV-1 clade 
B and C, and measuring the levels of the interactions (Figure 3.11). Fully folded and 
assembled kCD4-IgG2wt and kCD4-IgG2S60C heterotetramers were expected to bind 
immobilised gp120. As positive controls, NIH PRO 542, 2dsCD4wt and 2dsCD4S60C 
were also passed over the same panel of immobilised gp120s (Figure 3.11). The 
negative control used in the study was culture supernatant obtained from mock 
transfections (Figure 3.11).  
After passing the analytes over the six immobilised gp120s, MAb 17b was also 
passed over the flow cells to assess if it would bind the CoRbs of gp120, exposed by 
the analytes. 
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The engagement of gp120 by CD4 induces conformational changes in gp120 which 
expose the gp120 co-receptor binding site (CoRbs), allowing MAb 17b to bind the 
CD4 induced epitope (CD4i) [106, 110, 154, 172, 243-246]. Previous studies by 
Sullivan et al (1998) showed that the binding of MAb 17b to monomeric gp120 is 
minimal to none, without the prior engagement of gp120 by a CD4 moiety. If MAb 
17b binds to gp120 minimally without the prior engagement of CD4, amounts of MAb 
17b observed to bind gp120 increase as increasing amounts of CD4 are added to 
the reaction [110]. 
SPR data showed that kCD4-IgG2wt, NIH PRO 542, 2dsCD4wt and 2dsCD4S60C were 
all capable of binding the panel of six gp120s, but kCD4-IgG2S60C was not detected 
to bind any of the gp120s (Figure 3.11 A to F). For the analytes that bound gp120, 
three phases in the sensorgrams were observed: an association, equilibrium and 
dissociation phase. 
In view of the low amounts of heterotetrameric kCD4-IgG2S60C protein (approximately 
12 ng) present in the supernatant passed over the gp120s, it was not surprising that 
no binding was observed. The RU levels for all the kCD4-IgG2S60C-gp120 
interactions were similar to those registered by the negative control with gp120s 
(Figure 3.11 A to F). The supernatant containing minimal amounts of 
heterotetrameric kCD4-IgG2S60C was observed to expose the CoRbs of gp120 CN54, 
SF162, gp120 ZM and Bal (Figure 3.11 G, H, K and L). This result was unexpected 
since MAb 17b was observed to bind to these gp120s minimally without the prior, 
detectable engagement of kCD4-IgG2S60C or components thereof. 
The abilities of kCD4-IgG2wt, NIH PRO 542, 2dsCD4wt and 2dsCD4S60C to induce the 
exposure of the gp120s CoRbs were different, except in the case of gp120 ZM 
where none of the analytes were capable of exposing the CoRbs for MAb 17b 
binding (Figure 3.11 K). Notably, 2dsCD4wt was the only protein capable of eliciting 
the exposure of the CoRbs of five gp120s (Figure 3.11 G to J and L). Remarkably, 
kCD-IgG2wt was capable of eliciting the exposure of gp120 SF162, IN, ZA and Bal 
CoRbs (Figure 3.11 H, I, J and L) as NIH PRO 542 and 2dsCD4S60C and 2dsCD4wt. 
Although kCD4-IgG2wt, NIH PRO 542 and 2dsCD4S60C bound to gp120 CN54, they 
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could not elicit the exposure of the gp120 CN54 CoRbs (Figure 3.11 A and G, 
respectively). 
Overall, these results pointed to the fact that kCD4-IgG2wt was fully assembled and 
folded, but also bound various gp120s like NIH PRO 542, 2dsCD4wt and 
2dsCD4S60C. 
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The objective of this study was to generate the kCD4-IgG2wt protein which was 
structurally and functionally identical to PRO 542. An additional objective was to 
produce a mutant form of kCD4-IgG2wt containing an S60C mutation (kCD4-
IgG2S60C) in the CD4 portion. 
The S60C mutation in 2dsCD4 was previously shown to increase the affinity of CD4 
for gp120  [180], therefore, kCD4-IgG2S60C was intended to have enhanced binding 
activity against gp120, relative to kCD4-IgG2wt and PRO 542 obtained from the NIH. 
The pKHwt and pKLwt constructs designed in this study were capable of successfully 
producing the kCD4-IgG2wt HC and LC proteins in HEK293T cells, respectively. 
Concurrently, the pKHS60C and pKLS60C constructs designed in this study were 
capable of producing the kCD4-IgG2S60C HC and LC proteins, respectively. The 
production of assembled and secreted heterotetrameric kCD4-IgG2wt was attained 
by the co-transfection of pKHwt and pKLwt constructs in HEK293T cells. The 
HEK293T cells also achieved assembly of heterotetrameric kCD4-IgG2S60C, by the 
co-transfection of pKHS60C and pKLS60C, but the amounts of secreted kCD4-IgG2S60C 
heterotetramer were far lower compared to secreted heterotetrameric kCD4-IgG2wt. 
It was suspected, however, that the S60C mutation may have affected the proper 
folding of the heterotetramer, thus delaying or reducing the secretion of the 
heterotetramer into the culture supernatant. In addition, relatively large amounts of 
uncoupled kCD4-IgG2S60C HC and LC were present in the supernatant suggesting 
that heterotetrameric kCD4-IgG2S60C may be unstable in the culture supernatant. 
Although the heterotetrameric kCD4-IgG2wt and kCD4-IgG2S60C proteins were 
purified with limited success using different Protein-A affinity chromatography 
protocols, both proteins were observed to bind Protein-A agarose beads as NIH 
PRO 542, indicating that the Fc portions of both proteins were fully folded. The 
structural integrity of the kCD4-IgG2S60C CD4 portion could not be determined; 
however the kCD4-IgG2wt CD4 portions were fully folded as they could bind gp120 
Bal like NIH PRO 542.   
According to SPR data generated in this study, kCD4-IgG2wt was capable of binding 
to six different gp120 from HIV-1 clades B and C, and inducing their CoRbs like NIH 
102 
 
PRO 542, 2dsCD4wt and 2dsCD4S60C. The low amounts of expressed 
heterotetrameric kCD4-IgG2S60C prevented the determination of its structural integrity 
and functional specificity in SPR studies. 
Overall, the design and production of kCD4-IgG2wt which was structurally and 
functionally identical to NIH PRO 542, was successful and showed that our 
strategies in generating functional CD4-Immunoglobulin fusion proteins were 
comparable in efficacy to strategies employed by other groups. This study showed 
that functional CD4-based fusion proteins with activity against gp120 can be 
generated according to our strategies.  
Future studies are aimed at improving the yields of kCD4-IgG2wt and kCD4-IgG2S60C 
by modifying the expression vectors for enhance protein production in mammalian 
cells or optimizing production of the proteins in bacterial systems. We aim to also 
characterise the kinetics of the kCD4-IgG2wt-gp120 and kCD4-IgG2S60C-gp120 
interactions to see if our proteins have more potent activity than other CD4-based 
agents described by other groups. 
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Appendix 1: Nucleic acid analyses reagents and protocols 
 
1.1 LB Broth 
Ten grams of tryptone (Oxoid, Cambridge, England) was combined with 10 g of 
yeast extract (Biolab, South Africa), 15 g of NaCl (Merck, Darmstadt, 
Germany) and dissolved in 1 L of dH2O. The broth was autoclaved at 121 °C 
for 20 minutes and used when it had cooled to a temperature of 20 °C.  
 
1.2 LB agar plates 
Thirty-five grams of LB agar powder (Sigma-Aldrich; St. Louis, USA) was 
dissolved in 1 L of sterile dH2O. The dissolved agar powder was autoclaved at 
121 °C for 20 minutes and used once it had cooled to 20 °C. Ten millilitres of 
the dissolved LB agar was poured in sterile petri dishes (available in our 
laboratory). The plates were used once the LB agar had solidified.  
 
1.3 Ampicillin 
One hundred milligrams of ampicillin (available in our laboratory) was 
dissolved in 1 mL of 75% solution of absolute ethanol (Merck; Darmstadt, 
Germany). This solution was filtered using a 0.22 micron filter (Millipore; 
Massauchusetts, USA) and regarded as the 1000X stock. The stock solution 
was stored at -20 °C when not in use.  
 
1.8 70% Isopropanol 
Seventy millilitres of absolute isopropanol (Saarchem; South Africa) was added 
to 30 mL of sterile dH2O and mixed thoroughly. 
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1.9 70% ethanol 
Seventy millilitres of absolute ethanol (Merck; Darmstadt, Germany) was 
added to 30 mL of sterile dH2O and mixed thoroughly. 
 
1.10 50X TAE buffer 
In 1L of sterile dH2O; 242 g of tris (Sigma-Aldrich; St. Louis, USA), 51 mL of 
glacial acetic acid (Merck; Darmstadt; Germany) and 100 mL of 0.5 M sodium- 
EDTA was dissolved. The solution was corrected to have a pH of 8 using 
concentrated HCl (Merck, Darmstadt; Germany). 
 
1.11 0.7% agarose gel 
To make a 0.7% agarose gel, 0.7 g of agarose powder (Sigma-Aldrich; St. 
Louis, USA) was added to 100 mL of 1X TAE buffer (refer to 1.10). The mixture 
was heated in a microwave until all the powder had dissolved. When the 
solution had cooled to approximately 40 °C, 5 µg of ethidium bromide 
(Promega; Madison, USA) was added to the agarose solution. The solution 
was then cast and used once it had solidified. 
 
1.12 6X loading buffer 
Six times loading was made by adding 25 mg bromophenol blue (Fluka chemika, 
Buchs, Switzerland) and 3 mL glycerol (Saarchem; Wadeville, South Africa) to 10 
mL of dH2O. DNA samples were diluted with loading buffer to give a final volume of 
15 µL before they were loaded in the wells of agarose gel. 
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Appendix 2: Protein expression and characterisation related reagents  
 
2.1 DMEM additives 
DMEM (Sigma-Aldrich; St. Louis, USA) was supplemented with 10 mM of 
Glutamax™ L-glutamine (Invitrogen; California, USA) and 10% fetal bovine serum 
(FBS) (Sigma-Aldrich; St. Louis, USA), unless otherwise stated. 
 
2.2 SFM II additives 
SFM II was supplement with 10 mM of Glutamax™ L-glutamine (Invitrogen; 
California, USA) only. 
 
2.3 SDS-PAGE reagents and protocol  
 
4X stacking gel buffer 
Three grams of tris (Sigma-Aldrich; St. Louis, USA) was added to 40 mL of 
ddH2O and the solution was adjusted to have a pH of 6.8 with concentrated 
HCl (Merck; Darmstadt, Germany). Fifty millilitres of sterile dH2O were added 
thereafter and the solution was stored for up to 3 months in the dark when not 
used. 
 
4X running gel buffer  
To make the 4X running gel buffer, 36.3 g of tris (Sigma-Aldrich; St. Louis, 
USA) was added to 150 mL of sterile dH2O. The solution was adjusted to have 
a pH of 8. 8 with HCl (Merck; Darmstadt, Germany), topped up with ddH2O to a 
final solution of 200 mL and then stored at 4 °C for up to 3 months in the dark 
when not used. 
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10% SDS solution 
Five grams of SDS (Merck; Darmstadt, Germany) was added to 45 mL of 
ddH2O and the solution was stored at room temperature for up to 6 month if 
not used. 
 
10% (W/V) ammonium persulphate solution 
An amount of 0.1 g of ammonium persulphate (Sigma-Aldrich; St. Louis, USA) 
was added to 900 µL of ddH2O. The solution was used on the day it made and 
not stored. 
 
Running gel overlay 
Absolute isopropanol (Merk, Darmstadt, Germany) was used as the running gel 
overlay. 
 
2X treatment buffer 
One and a half millilitres of 2X stacking gel buffer, 4 mL of 10% of SDS 
solution, 2 mL of glycerol (Merck; Darmstadt, Germany), 2 mg of bromophenol 
blue (Fluka chemika, Buchs, Switzerland) and 1.5 mL of sterile dH2O were 
mixed together to make 2X treatment buffer. For reducing SDS-PAGE 
conditions, 100 µL of beta-mercaptoethanol (Sigma-Aldrich, St. Louis, USA) 
was added per 900 µL of 4X treatment buffer. The treatment buffer was made 
in 500 µL aliquots and thawed to 20 °C before. Unused 2X treatment buffer 
was kept at -20 °C. 
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Tank Buffer 
To make one litre of tank buffer; 3.3 g of tris (Sigma-Aldrich, St. Louis, USA), 
28.8 g of glycine (Saarchem; Wadeville, South Africa) and 2 g of SDS (Merk, 
Darmstadt, Germany) were dissolved in 1 L of sterile dH2O. 
 
Coomassie stain solution 
Five hundred millilitres of absolute methanol (Merck; Darmstadt, Germany), 
100 mL of acetic acid (Sigma-Aldrich, St. Louis, USA) and 400 mL of sterile 
dH2O were combined, then 0.25 g of coomassie R-250 (Fluka chemika, Buchs, 
Switzerland) was dissolved in the solution. 
 
Destain solution 
To make destain solution; one adds 50 mL of absolute ethanol (Merk, 
Darmstadt, Germany) to 70 mL of acetic acid and 880 mL of sterile dH2O. 
 
Protocol 
To make 60 mL of running gel solution for two 1.5 mm thick SDS-PAGE gels; 
8.75 mL of monomer solution (Sigma-Aldrich; St. Louis, USA), 15 mL of 4X 
running gel buffer (refer to appendix 2.3), 0.6 mL of 10% SDS (refer to 
appendix 2.3) and 26.6 mL of sterile dH2O were combined and mixed. To 
commence polymerisation of the acrylamide, 300 µL of 10% (w/v) ammonium 
persulphate (Sigma-Aldrich; St. Louis, USA) and 20 µL of TEMED (Sigma-
Aldrich; St. Louis, USA) were added consecutively to the running gel solution 
and mixed thoroughly. The running gel solution was cast in Bio-Rad plates 
(Bio-Rad; Hercules, USA) for polymerisation for approximately 45 minutes till 
they had solidified.  
To make 30 mL of stacking gel solution for two 1.5 mm thick SDS-PAGE gels; 
2.66 mL of monomer solution (Sigma-Aldrich; St. Louis, USA), 5 mL of stacking 
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gel buffer (refer to appendix 2.3), 0.2 mL of 10% SDS solution (refer to 
appendix 2.3) and 12 mL of sterile dH2O were combined and mixed thoroughly. 
To commence polymerisation of the acrylamide, 100 µL of 10% (w/v) 
ammonium persulphate (Sigma-Aldrich; St. Louis, USA) and 10 µL of TEMED 
(Sigma-Aldrich; St. Louis, USA) were added consecutively to the stacking gel 
solution. The stacking gel solution was then cast in Bio-Rad plates (Bio-Rad; 
Hercules, USA) for a minimum of 45 minutes until they had solidified. 
 
2.4 Western blotting reagents 
 
10 X TBS 
Ten grams of NaCl (Merk, Darmstadt, Germany), 30 g of tris (Sigma-Aldrich, 
St. Louis, USA) and 2 g of KCl (Calbiochem; California, USA) were dissolved 
in 900 mL of sterile dH2O. The pH of the solution was adjusted to 7.4 with HCl 
(Merk, Darmstadt, Germany) before 100 mL of sterile dH2O was added to 
complete the solution. 
 
1 X TTBS 
One hundred millilitres of 10X TBS (Appendix 2.4) was added to 900 mL of 
sterile dH2O. To complete the solution, 1 mL of tween-20 (Sigma-Aldrich, St. 
Louis, USA) was then dissolved in the solution. 
 
 
Transfer buffer  
Each litre of transfer buffer contains 800 mL of tank buffer (Appendix 2.3) and 
200 mL of absolute methanol (Merck, Darmstadt, Germany). 
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Primary antibody: MT310 (Santa Cruz Biotechnology INC; California, USA) 
Three microlitres of stock MT310 (Santa Cruz Biotechnology INC; California, 
USA) was diluted in 3 mL of 1X TTBS (Appendix 2.4) and poured onto the 
surface of nitrocellulose membrane and allowed to incubate away from light, 
undisturbed for a 1 hour. 
 
Secondary antibody: anti-mouse Ig horseradish peroxidase-linked whole 
antibody (GE Healthcare; Buckinghamshire, England) 
Three microlitres of stock anti-mouse Ig horseradish peroxidase-linked whole 
antibody (GE Healthcare; Buckinghamshire, England) was diluted in 3 mL of 
1X TTBS (Appendix 2.4) and poured onto the surface of nitrocellulose 
membrane and allowed to incubate away from light, undisturbed for a 1 hour.  
 
2.5 Protein-A agarose beads (Bio-Rad; Hercules, USA)   
The Protein-A agarose beads (Bio-Rad; Hercules, USA) were stored in 1X PBS 
(Sigma-Aldrich; St. Louis, USA) containing 0.1% sodium azide (Sigma-Aldrich; St. 
Louis, USA). Before use, the beads were washed thoroughly with 1X PBS (Sigma-
Aldrich; St. Louis, USA) without sodium azide (Sigma-Aldrich; St. Louis, USA).  
 
2.6 Binding buffer (0.02 M sodium phosphate pH 6.5) 
Binding buffer was made combining 37.5 mL of 0.1 M sodium phosphate (di-sodium 
salt) solution (Fluka chemika, Buchs, Switzerland) with 62.5 mL of sodium 
phosphate (mono-sodium salt) (Sigma-Aldrich; St. Louis, USA) solution and 
dissolving the two combined solutions in 400 mL of sterile dH2O. The solution was 
filtered using a 0.22 micron Millipore filter (Millipore; Massauchusetts, USA) before 
use. Unused buffer was stored at 4 °C for up to 1 month. 
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2.7 Elution buffer (0.1 M citric acid buffer at pH 3.5) 
The elution buffer was made by combining 31.5 mL of trisodium citrate 
dehydrate (Merck; Darmstadt, Germany) solution with 68.5 mL of sodium 
citrate monohydrate (Sigma-Aldrich; St. Louis, USA) solution. The solution was 
filtered using a 0.22 micron Millipore filter (Millipore; Massauchusetts, USA) before 
use. Unused buffer was stored at 4 °C for up to 1 month. 
 
2.8 Neutralisation solution (1M tris-HCl at pH 9) 
A mass of 6.057 g of tris (Sigma-Aldrich; St. Louis, USA) was dissolved into 50 
mL of sterile dH2O and the pH of solution was corrected to a value of 9 using 
concentrated HCl (Merck; Darmstadt, Germany). 
 
2.9 Regeneration buffer (50 mM NaCl and 50 mM NaOH) 
To make the regeneration solution; 0.14 g of NaCl (Sigma-Aldrich; St. Louis, 
USA) and 0.1 g of NaOH (Sigma-Aldrich; St. Louis, USA) were dissolved 
together in 500 mL of sterile dH2O.  
 
2.10 Anti-gp120 antibody cocktail  
The ID6, Chessie supernatant and NEA antibodies were diluted in a 1: 1000 with 1X 
TTBS (Appendix 2.4), applied to the nitrocellulose blot on a flat surface and allowed 
to incubate undisturbed for 1 hour. 
 
2.11 HBS 
HBS was made by combining 10 M hepes (Sigma-Aldrich, St. Louis, USA), 150 
mM NaCl (Sigma-Aldrich, St. Louis, USA), 3 mM EDTA (Calbiochem, 
Germany) and 0.01% tween-20 (Sigma-Aldrich, St. Louis, USA) in 2 L of sterile 
ddH2O. The pH of the buffer was adjusted to a value of 7. 4. The buffer was 
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filtered using a 0.22 micron Millipore filter (Millipore; Massauchusetts, USA) 
before use. 
 
 
 
 
